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   ABSTRACT 
 
Many studies have reported low cure rates for multidrug-resistant tuberculosis (MDR-
TB) patients and MDR-TB patients co-infected with human immunodeficiency virus 
(HIV). However, little is known about the effect of HIV infection and antiretroviral 
therapy on the treatment outcomes of MDR-TB in South Africa. Therefore, the objectives 
of the study are: to find out whether HIV infection and interactions between ARVs and 
second line anti-TB drugs have an impact on the following MDR-TB treatment 
outcomes: cure rate and treatment failure at Brewelskloof Hospital. MDR-TB patients 
were treated for 18-24 months. 
The study was designed as a case-control retrospective study comparing MDR-TB 
treatment outcomes between HIV positive (cases) and HIV negative patients (controls).  
Patients were included in the study only if they complied with the following criteria: 
sensitivity to second line anti-TB drugs, MDR-TB infection, co-infection with HIV (for 
some of them),  male and female patients, completion of treatment between 1 January 
2006 and 31 December 2008. Any patients that presented with extreme drug-resistant 
tuberculosis (XDR-TB) were excluded from the study. 
Data were retrospectively collected from each patient’s medical records. There were a 
total of 336 patients of which 242 (72%) were MDR-TB patients and 94 (27.9%) MDR-
TB co-infected with HIV patients. Out of the 242 MDR-TB patients, 167 (69.2%) were 
males and 75 (30.7%) were females. Of the 94 patients with MDR-TB co-infected with 
HIV, 51 (54.2%) males and 43 (45.7%) females.  
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Patients with multidrug-resistant tuberculosis co-infected with HIV who qualify for 
antiretroviral therapy were treated with stavudine, lamivudine and efavirenz while all 
MDR-TB patients were given kanamycin, ethionamide, ofloxacin, cycloserine and 
pyrazinamide. The cure rate of MDR-TB in HIV (+) patients and in HIV (-) patients is 
34.5% and 30 % respectively. There is no significant difference between both artes (p-
value = 0.80). The MDR-TB cure rate in HIV (+) patients taking antiretroviral  drugs and 
in HIV (+) patients without antiretroviral therapy is 35% and 33% respectively. The 
difference between both rates is not statistically significant. The study shows that 65 
(28.0%) patients completed MDR-TB treatment but could not be classified as cured or 
failure,  29 (12.5%) patients failed, 76 (32.7%) defaulted, 18 (7.7%) were transferred out 
and 44 (18.9%) died. As far as treatment completed and defaulted is concerned, there is 
no significant statistical difference between HIV (+) and HIV (-) The number of patients 
who failed the MDR-TB treatment and who were transferred out is significantly higher in 
the HIV (-) group than in the HIV (+) group. Finally the number of MDR-TB patients 
who died is significantly higher in the HIV (+) group). 
 The median (range) duration of antiretroviral therapy before starting anti-tuberculosis 
drugs is 10.5 (1-60) months. 
According to this study results, the MDR-TB treatment cure rate at Brewelkloof hospital 
is similar to the cure rate at the national level. The study also shows that HIV infection 
and antiretroviral drugs do not influence any influence on MDR-TB treatment outcomes. 
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CHAPTER ONE  
 
 
INTRODUCTION 
 
 
 
1.1 Background information 
Multidrug-resistant tuberculosis is usually the result of irregular adherence to TB treatment and 
is identified when there is resistance to rifampicin and isoniazid on sputum culture sensitivity 
testing Department of Health (National, 1993). Multidrug-resistant tuberculosis (MDR-TB) is a 
public health problem in developing countries (Thelma E et al, 1999) and particularly in South 
Africa (WHO, 2010).  In South Africa, MDR-TB is treated in designated hospitals. In the 
Western Cape Province, there are four MDR-TB hospitals.  These are Brooklyn Chest hospital 
(BCH) and DP Marais hospital in the cape metropole region, Harrycomay hospital in George and 
Brewelskloof hospital in Worcester. This study was carried out at the Brewelskloof hospital.  
According to the Department of Health (National, 2006), MDR-TB cure rate was between 30-
50%.  This cure rate is even lower in patients with human immunodeficiency virus (HIV) 
infection (Nottel HS et al, 1991).  There are however, limited data about MDR-TB treatment 
outcomes and the prevalence of HIV among MDR-TB patients (Sanchez-Padila  et al, 2009-
2010). 
 Also, the influence of HIV on treatment outcomes of MDR-TB needs to be investigated. In 
doing this, the influence of HIV infection on the treatment outcomes of MDR-TB 
(www.mdpi.com, 2012), one needs to determine whether the interaction between antiretroviral 
(ART) drug and second-line anti-TB drugs may have an impact on MDR-TB treatment 
outcomes. 
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1.2 Motivation for the study 
South Africa has an estimated 14,000 incidence cases of MDR-TB every year (WHO, 2010) and 
33% of HIV prevalence; Department of Health (Provincial, 2007) and (City of Cape Town, 
2009). To date, there has been limited data available on the prevalence of MDR-TB (Helen SC et 
al, 2009) in South Africa.  Investigations are needed in order to understand the main causes of 
unsuccessful treatment of MDR-TB. Many of these MDR-TB patients are unknown to the health 
service (Park MM et al 2007), often because they have not been diagnosed and not on treatment 
Department of Health (City of Cape Town, 2009). Though there was a study in Khayelitsha in 
2009, Department of Health (City of Cape Town, 2009) none has been done in the Brewelskloof 
hospital. There is an urgent need to quantify the extent of the drug-resistant tuberculosis 
epidemic in these communities in order to advocate for and develop strategies for control (Park 
MM et al, 2007). 
It is against this background that this study seeks to investigate whether HIV infection and drug 
interactions between ARVs and second line anti-TB drugs (Kawal V et al, 2005) have an impact 
on the following MDR-TB treatment outcomes: cure rate and treatment failure at Brewelskloof 
Hospital.  
1.3 The aim of the study 
The aims of the current study are: (1) to find out the treatment outcomes of MDR-TB; (2) to 
assess the influence of HIV infection on MDR-TB treatment outcomes and (3) to find out 
whether the interaction between ARV drugs and second-line anti-TB drugs has any impact on 
MDR-TB (Goble M et al, 2006) treatment outcomes. 
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    CHAPTER TWO 
 
LITERATURE REVIEW 
 
2.1 The global picture of tuberculosis and human immunodeficiency virus  
2.1.1 Incidence of tuberculosis 
 
Incidence of tuberculosis is greatest among those with conditions impairing immunity (Corbett et 
al; 2003), such as HIV infection. Tuberculosis is the world’s greatest infectious killer of women 
of reproductive age and leading cause of death among those infected with HIV and AIDS 
globally (www.Maxpedia.org, 2012). There has been an increase in TB (World TB Day, 2008) 
cases from 6.6 million in 1990 to 8.3 million in 2000. The WHO has declared TB to be a global 
public health emergency, with an estimated one-third of the world’s population being infected 
with Mycobacterium tuberculosis (M.Tb) (www. Microbewiki.Kenyon.edu, 2012).  
In 2006, estimated number of active TB carriers is around 20 million worldwide with more than 
3 million deaths annually (Zignol et al, 2006). In 2006, it was also discovered that the incidence 
of TB has been increasing globally in recent years (Lan T.Ho-Pharm, 2010), partially due to the 
HIV epidemic (Aziz et al, 2006). In addition, there has been an increase in the occurrence of 
strains of Mycobacterium tuberculosis that are resistant to (www.thebody.com, 2012) currently 
used chemotherapy (Aziz et al, 2006). In 2005, there were an estimated 8.8 million new cases of 
tuberculosis worldwide (www.biomedcentral.com, 2012); and 9.24 million in 2006 (WHO, 
2007). Tuberculosis continues to infect an estimated one-third of the world’s population, to cause 
disease in 8.8 million per year, and to kill 1.6 million of those infected (www.japi.org, 2012). A 
study by the WHO covering the five regions of the world estimated numbers of TB cases in 2007 
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to be spread as follows: Asia (55%), Africa (31%), Eastern Mediterranean region (6%), the 
European Region (5%), and the Region of the Americas (3%) (www.who.int, 2010).  
The WHO reported that the resistance includes resistance to isoniazid and rifampicin in 
combination, followed by the deadly, almost incurable, emergence of MDR-TB (WHO, 2009). 
The WHO stated that the Asian region is the worst affected, as more than 50% cases of TB 
occurred in India and China (K. Flouyd. 2012). In 2009, WHO estimated that the incidence cases 
of TB to be 9.27 million (WHO, 2010). 
2.1.2 Prevalence of human immunodeficiency virus and acquired immunodeficiency 
syndrome  
An estimated 34.0 million people were living with HIV as of 2010; 3.4 million of them were 
children under 15 years, and about 16.8 million were women. Every day, over 7,000 persons 
became infected with HIV and about 5,000 persons died from AIDS, mostly because of 
inadequate access to HIV prevention care and treatment services (WHO, 2010). Roughly 17.1 
million children under the age of 18 have lost one or both parents to AIDS, and millions more 
have been affected, with a vastly increased risk of poverty, homelessness, school dropout, 
discrimination and loss of life opportunities (www.extremeresponse.info, 2012). These hardships 
include illness and death. Of the estimated 1.8 million people who died of AIDS-related illnesses 
in 2010, children under 15 years accounted for 250,000 (WHO, 2010). 
Human immunodeficiency virus is the main reason for failure to meet TB control targets in high 
HIV settings. TB is a major cause of death among people living with HIV. Sub-Saharan Africa 
bears the brunt of the HIV fuelled TB epidemic. The rapidly increasing HIV epidemic in other 
parts of the world could also increase the number of HIV-related TB cases. In order to control 
TB in high HIV settings, the Stop TB strategy includes collaborative TB/HIV activities. These 
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collaborative TB/HIV activities have the objectives of creating the mechanism of collaboration 
between TB and HIV/AIDS programmes, reducing the burden of TB among people living with 
HIV and reducing the burden of HIV among TB patients (www.who.int, 2012). 
2.1.3 Mortality or morbidity of tuberculosis, human immunodeficiency virus and 
acquired immunodeficiency syndrome  
 
In 2009 there were 9.4 million new TB cases, including 1.1 million cases among people with 
HIV; 1.7 million people, (of whom 380,000 were women with HIV-positive) died from TB, an 
average of 4,700 deaths a day (WHO, 2010). Tuberculosis is one of the three main causes of 
death among women aged 15 to 44 (www.pulsepakistan.com, 2012). In 2007, WHO indicated 
there were 9.27 million TB and HIV incident cases, of which an estimated 1.37 million (15%) 
was HIV positive; 79% of these HIV positive cases were in the Africa Region and 11% were in 
the South-East Asia Region (www.who.int, 2012). Globally, however, TB incidence is falling 
slowly, and at least three of six WHO regions are on track to achieve global targets for reducing 
the number of cases and deaths that have been set for 2015 (WHO, 2010). The statements above 
have shown that that there is increase in the TB global control. 
2.2 The situation of tuberculosis and HIV – infection on the African continent 
2.2.1 Tuberculosis 
The African region accounts for more than a quarter of the global TB burden, with an estimated 
2.4 million cases and 540,000 deaths annually (www.tbtoolkit.org, 2012).  It is also noted that 
out of the 400,000 people worldwide infected with MDR-TB in 2008, 14,000 died (WHO, 2009). 
It has been discovered that inadequate treatment of TB has been the cause of MDR-TB 
(www.whqhbdoc.who.int, 2010). 
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2.2.2 Human immunodeficiency virus and acquired immunodeficiency syndrome   
Human immunodeficiency virus and AIDS are a major public health concern and cause of death 
in Africa. Africa is home to about 14.5% of the world population. It is estimated to be home to 
67% of all people living with HIV and 72% of all AIDS death in 2009 (www. danpritcherd.com, 
2012). 
According to UNAIDS, some countries has suffered from political factors for not using modern 
medicine, where leaders have denied the link between HIV and AIDS, favoring alternative 
medicine (UNAIDS, 2010). Despite the lack of scientific acceptance, AIDS unconfirmed 
statements has had a negative significant impact, especially in South Africa; where our leader 
ignored the call for introduction of ARVs in the treatment of HIV patients (UNAIDS, 2010).  
African continent also suffered from economic factors of lack of money, natural disasters and 
conflicts food, shelter or other sources (Online. http://www.villagevoice.com, 2011). A minority 
of scientists claim that as many as 40% HIV infections in African adults may be caused by 
unsafe medical practices rather than by sexual activity (Samuel and Fiona, 2009). 
There is different regional analysis in HIV/ AIDS in Africa: (1) East-central Africa-Kenya 
having the highest adult HIV prevalence and Tanzania having the highest death in 2009 (WHO, 
2010). (2) West Africa: Nigeria having highest adult HIV and AIDS prevalence and death in 
2009. The region has generally high levels of infection of both HIV-1 and HIV-2. Nigeria has the 
second largest number of people with HIV in Africa after South Africa (WHO, 2010). (3) In the 
mid-1980s, Southern Africa HIV and AIDS are virtually unheard of, but it is now the worst-
affected region in the world. Of the eleven Southern Africa countries at least seven are estimated 
to have an infection rate of over 15% (Africa, 2011). Angola presents one of the lowest infection 
rates of 2.1% (www.Indexmundi, 2012). Most HIV infection found in Southern Africa is HIV-1, 
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the world’s most common HIV infection, which predominates everywhere except West Africa, 
which is home to HIV-2 (http://www.Wikipedia.org, 2011). 
2.2.3 Tuberculosis, human immunodeficiency virus and acquired immunodeficiency 
syndrome 
 
In a survey of 17 (10%) African countries with tuberculosis, HIV and AIDS including South 
Africa, there were high burden of TB, HIV and AIDS in African countries. Data indicate 
resistance to single TB drug treatment; there is also a significant increase in Botswana, where 
some longitudinal data exist with joint HIV infection (Jones KDJ et al, 2006). 
2.3 The situation of tuberculosis and HIV – infection in the sub-Saharan Africa Region 
2.3.1 Tuberculosis 
 
Sub-Saharan Africa has been identified as a TB “hotspot”; this is not surprising given the poor 
TB cure rates in many of these countries (WHO, 2010). South Africa has the highest cases of TB 
in Africa (Kent G, 2010). The WHO in 2010 revealed that the sub-Saharan region accounts for 
more than a quarter of the global burden of TB with an estimated 2.4 million TB cases and 
540,000 TB deaths annually (www.tbtoolkit.org, 2012).  
 2.3.2 Human immunodeficiency virus and acquired immunodeficiency syndrome 
 
A UNAIDS/WHO study on HIV in sub-Saharan Africa. In 2009, (Dater Anaid et al, 2010) 
revealed that 68% of all people living with HIV are in sub-Saharan Africa and 3.9% of these 
were receiving antiretroviral therapy (UNAIDS, 2010). An estimated 22.5 million people were 
living with HIV in sub-Saharan Africa (www.danadamsgh.com 2011), including minor children 
(UNAIDS, 2010). The five countries experiencing the worst HIV/AIDS epidemic in sub-Saharan 
Africa are discussed as followed: Botswana has 320,000 people living with HIV/AIDS (Holtz 
TH, 2011) (24.8%), Lesotho has 290,000 people living with HIV/AIDS (23.6%), South Africa 
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has 5,600,000 people living with HIV/AIDS (17.8%), Zimbabwe has 1,200,000 people living 
with HIV/AIDS (14.3%) and Zambia has 980,000 living with HIV/AIDS (13.5%); the 
percentages were based on the total population in each country (Online. http://www.village.com, 
2011). These figures show that sub-Saharan Africa is the region most affected by TB and HIV 
(www.stoptb.org, 2009), consequently leading to high morbidity and mortality. These data 
should be a wake-up call for all African leaders and stakeholders. 
2.3.3 Tuberculosis, human immunodeficiency virus and acquired immunodeficiency 
syndrome 
 
In 2009 data relating to TB and HIV in sub-Saharan Africa showed that there were 1.37 million 
new cases of TB sub-Saharan among HIV positive people (Jarvis M, 2010). There were 14 
million people who are co-infected with TB and HIV globally; around 80% of those who are co-
infected live in sub-Sahara Africa (www.aidsmap.com, 2011). 
2.4 The South African situation of tuberculosis and HIV-infection 
2.4.1 Drug resistance to tuberculosis 
 
In South Africa, TB constitutes more than 80% of all notifiable diseases Department of Health 
(National, 1990). In 1996 the WHO and NDOH conducted a combined review of the TB Control 
Program in South Africa. It was reported that drug-resistant TB has become a public health 
concern because of past TB history, re-infection with drug-resistant strains and inadequate 
treatment and poor treatment adherence on the part of the patients (WHO, 1996).   
Also, there has been an increase in the number of patients who are resistant to first-line anti-TB 
drugs (www.who.int, 1996). In 2006, the annual tuberculosis incidence rate was estimated to be 
628 cases per 100,000 of the population per annum (www.ukpmc.ac.uk, 2012); in a population 
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of 47.9 million people (WHO, 2008). The WHO estimated that in 2009, 3.3% of all new TB 
cases were MDR-TB (WHO, 2009).  
The observation, however, that tubercule bacillus can survive in cells and tissues of the patient 
despite the adequate and regular administration of drugs leads one to query reasons other than 
poor compliance as an explanation for treatment relapses and drug resistance (March et al, 1997). 
The WHO estimates that there are more than 14,000 MDR-TB incident cases in South Africa 
each year (www.msf.org.za, 2009).  
2.4.2 Human immunodeficiency virus and acquired immunodeficiency syndrome 
In 2006, UNAIDS estimated HIV prevalence in South Africa to be 17.8% with household 
(17.2%) and antenatal (18.3%) statistics (National, 2010). South African National Statistics 
stated that in 2007 of an estimated total population of 47.9 million people, an estimated 5.7 
million people were living with HIV (www.ukpmc.ac.uk, 2012) and, at the end of 2009, the 
figures included 300,000 children under 15 years old (www.avert.org, 2011). It predicts that 
South Africa will exceed 6 million people living with HIV by 2015, by which time around 5.4 
million South Africans would have died of AIDS (www.griffintheatre.com.au, 2012). The 
provinces with the highest HIV prevalence were: Kwazulu-Natal (39.5%), Mpumalanga (34.7%), 
Free State (30.1%) and the North-West (30%). The Northern Cape and Western Cape recorded 
the lowest prevalence (17.2% and 16.9%) respectively (www.avert.org, 2011). 
2.4.3 Tuberculosis, human immunodeficiency virus and acquired immunodeficiency 
syndrome 
 Tuberculosis disease synergistically accelerates the progression of HIV infection to AIDS by 
inciting viral replication in immunologically activated CD4 cells (Tolu Oni, 2009).  
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The two pandemics of TB and HIV fuel each other and the statistics show the risk of TB after 
HIV infection. The annual incidence of TB disease doubles within the first year of HIV infection 
(www.ukpmc.ac.uk, 2012).  
The WHO reported that in South Africa, more than half of TB patients tested for HIV are 
seropositive (www.ukpmc.ac.za, 2011). The City of Cape Town conducted research in 2007 on 
antenatal HIV prevalence and estimated it to be 30%. The case notification rate for TB was at 
least 1,500 per 100,000 people per year – among the highest TB incidence rates in the world 
(www.ukpmc.ac.za, 2011). Siyanyinqoba states that HIV and TB are twin epidemics: nearly 70% 
of all people with TB are also HIV positive (www.leeds.ac.uk, 2010). It is imperative at this 
juncture to say that having HIV and contracting TB does not mean a “death sentence” unless the 
patients refuse to take their prescribed medications. Because of the association between HIV and 
TB (Karen, 2011) has prompted the South African Government to have Antiretroviral Treatment 
Guidelines formulated for proper management of adult and adolescents patients. 
The combination chemotherapy of five to six drugs assumes a low probability of simultaneous 
resistance to all drugs in the regimen (www.pubmedcentralnih.gov, 2010). Researchers have 
reported that, in patients with MDR-TB and in patients with MDR-TB co-infected HIV 
(www.tfcares.org 2010), and who taking co-trimaxozole preventative therapy (CTP) reduced 
mortality rates. In patients on ART with low CD4 counts or WHO stages 1, 2, 3 and 4 disease. 
Observational studies in Malawi, Ivory Coast and South Africa in a retrospective analysis 
showed 46% reduction in mortality rates of tuberculosis (Mwaungulu, 2004, Dean, 1999 and 
Hoffman, 2010).  
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2.5 Overview of multidrug-resistant tuberculosis 
Over the past decade, there has been an increase in the appearance of strains of TB that are 
resistant to anti-TB drugs. Multi-drug resistant TB is caused by TB strains that are resistant to 
the first line drugs INH and RIF (www.touchbriefing.com, 2010), which are considered to be the 
most potent drugs against drug-susceptible TB (Iseman, 2002; Sharma and Mohan, 2004). The 
molecular basis of drug resistance to TB is now largely understood (Garcia De VD et al, 2002). 
From a microbiological point of view, the resistance is caused by a spontaneous and random 
mutation in the MTB bacterial chromosome. This leads to amino acids substitutions in their 
target proteins (for example, beta -subunit of MTB RNA polymerase in case of rifampicin), 
which result in reduced susceptibility to specific drug, and thus, the drug, becomes ineffective 
against the mutant bacilli (Blanchard, 1996; Ramaswamy and Muser, 1998). 
Drug resistance is categorized into primary, acquired and initial resistance (Kochi et al, 1993; 
Loddenkemper et al, 2002). Primary resistance is resistance to anti-TB drugs in patients with no 
history of previous TB treatment, that is, treatment-naïve patients (www.Columbia.edu, 2011). 
Acquired resistance is resistance to anti-TB drugs from patients with previous treatment (Pinto 
WP, 2001), which could be one or more treatment. Initial resistance is referred to patients with 
primary resistance as well as those with undisclosed acquired resistance. 
Causes of drug resistance include many factors such as inadequate treatment regimens 
prescribed, poor drug supply and quality, misuse of (www.eqrosurveillance.org, 2011) anti-TB 
drugs, poor treatment compliance, treatment default and HIV co-infection (Iseman, 1993; Jain, 
1998; Sharma and Mohan, 2004). The HIV-infection epidemic has caused an explosive increase 
in TB incidence and may be contributing to the increase in MDR-TB infection (www.stoptb.org, 
2011). Outbreaks of MDR-TB infection and case-fatality rates reaching 83% among HIV-
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infected patients have been reported (www.caprisa.org, 2011). This suggests that the severe 
immune suppression, which occurs in HIV infected patients, appears to be a predisposing factor 
for the development of MDR-TB (www.medind.nih.in, 2011).  
2.6 The causes of drug resistance 
Recent findings on XDR- TB can no longer be considered as occurring in isolated outbreaks as it 
has been reported in 45 countries from all regions of the world (www.lib.bioinfo.pl, 2011). 
Human immunodeficiency virus has been associated as independent risk factors for infection 
with drug-resistant TB (www.lib.bioinfo.pl, 2011). Human immunodeficiency virus patients 
appear more likely to suffer from primary transmitted resistance as opposed to developing 
acquired resistance during the course of treatment for TB (www.lib.bioinfo.pl, 2011). New rapid 
diagnostic offer promise or provide clinically useful first-line drug susceptibility information but 
require validation in HIV patients and smear negative individuals. Therefore, MDR and XDR TB 
disproportionately affect HIV patients and results in increased morbidity and mortality 
(www.lib.bioinfo.pl, 2011). Unfortunately, at least one strain of M. tuberculosis in South Africa 
had already developed resistance to one or more of those second-line drugs by the time they were 
introduced. Drug susceptibility tests would have warned prescribers that the standard second-line 
regimen was unlikely to help the patient but was likely to lead to additional drug-resistance. But 
these tests were not performed or were not available. Indeed, the reduced efficacy of the regimen 
allowed the stain to survive and over time, develop resistance to other drugs. So there is need to 
increase the use of drug resistance surveillance programs to help forestall the development of 
drug-resistance in M. tuberculosis (www.blackherbals.com, 2011). 
Resistance to first-line drugs in most of the pathogens causing these diseases ranges from zero to 
almost 100%. In some instances, resistance to second and third line agents is seriously 
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compromising treatment outcomes. Added to this is the significant global burden of resistant 
hospital-acquired infections, the emerging problems of antiviral resistance and the increasing 
problems of drug resistance in the neglected parasitic diseases of poor and marginalized 
populations. This is WHO global strategy for containment of antimicrobial resistance (www. 
plumbot.com, 2011). 
Drug resistance caused by Mycobacterium tuberculosis develops when patients with tuberculosis 
cannot or do not comply with the medication regimen. A second line of drugs has been used to 
treat those infected with drug-resistant TB (www.nerve.in, 2011). This second-line medication 
regimen was adopted in South Africa in 2001 to treat drug-resistant TB. The worldwide 
emergence of drug-resistant has blunted and may reverse the benefits from the historic rollouts of 
ARVs (Sheela S, 2009).  
Drug resistance is the reduction in effectiveness of a drug such as an antimicrobial or an 
antineoplastic (www.mejfrm.com, 2007). It can develop naturally, but careless practices in drug 
supply and use are hastening the problem. The overuse of antibacterial cleaning products in the 
home may be producing strains of multi-antibiotics-resistant bacteria. The use and misuse of 
antimicrobials in human medicine and animal husbandary over the last 70 years has lead to the 
rise in the number and types of micro-organisms resistant to these medicines leading to death, 
increased suffering and disability and higher healthcare costs. Death from acute respiratory 
infections, diarrhoeal diseases, measles, AIDS, malaria and tuberculosis accounts for more than 
85% of the mortality from infections worldwide (WHO, 2010).  
2.7 Terminologies for multidrug-resistant tuberculosis treatment outcomes 
The following definitions were recommended by the World Health Organisation (WHO, 2003).  
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2.7.1 Case of tuberculosis 
 A patient in whom tuberculosis has been bacteriologically confirmed, or has been diagnosed by 
a clinician using other methods of diagnosis. 
2.7.2 Pulmonary tuberculosis, sputum smear positive  
Pulmonary TB, sputum smear positive stands for when two or more initial sputum smear 
examinations positive for Acid-Fast Bacilli (AFB). It is also when one sputum smear 
examination positive for AFB plus radiological abnormalities consistent with active pulmonary 
tuberculosis as determined by a clinician; or when one sputum smear positive for AFB plus 
sputum culture for M. tuberculosis (www. stoptb.org, 2009). 
2.7.3 Pulmonary tuberculosis, sputum smear negative  
A case of pulmonary tuberculosis which does not meet the above definitions for smear positive 
TB, in keeping with good clinical and public health practices, diagnostic criteria should include: 
at least three sputum specimens negative for AFB; radiographic abnormalities consistent with 
active pulmonary tuberculosis; no response to a course of broad spectrum antibiotics; and a 
decision by a clinician to treat with full course of anti-tuberculosis chemotherapy (www. 
stoptb.org, 2009). 
2.7.4 Extra-pulmonary tuberculosis 
This is tuberculosis that affects other organs than the lungs, for example, pleural layers, lymph 
nodes, abdomen, genitourinary tract, skin, joints and bones, meninges and so on. Disease should 
be based on one culture positive specimen, or histological or strong clinical evidence consistent 
with active extra-pulmonary tuberculosis, followed by a decision by a clinician to treat with full 
course of anti-tuberculosis chemotherapy (Abdul Majid W, 2010). 
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2.8 Terminologies for multidrug-resistant tuberculosis treatment outcomes 
The World Health Organisation (WHO, 2003) has classified the treatment outcomes of TB 
patients into different terms and defined as such (C-S Wang, 2008; Abdul M, 2010 ).  
2.8.1 New 
Are patient who has never had treatment for TB, or has taken anti-tuberculosis drugs for less 
than one month. 
2.8.2 Relapse 
A patient previously treated for TB who has been declared cured or treatment completed 
(www.childsurvival.com, 2009). 
2.8.3 Treatment failure 
A patient who, while on treatment, sputum is smear positive 5 months or later during the course 
of treatment. 
2.8.4 Return after default   
These are patients who return with confirmed MDR-TB after interruption of treatment for two 
months or more. 
2.8.5 After failure of first treatment  
These are patients who return after the first treatment (Regimen 1) has failed. 
2.8.6 After failure of re-treatment  
These are patients who return after the re-treatment (Regimen 2) has failed. 
2.8.7 Transfer-in  
Drug-resistant TB patients who have been transferred from another register for treatment of 
drug-resistant TB, to continue Regimen 4, are referred to as transfer-in patients. The receiving 
unit should report these patients’ treatment outcomes to the transferring unit so that it can report 
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their outcomes in the context in which they originally started regimen 4 treatment 
(www.stoptb.org, 2009). 
2.8.8 Cure 
 Patient who sputum smears is negative in the last month of treatment, and on at least one 
previous occasion. 
2.8.9 Treatment completed 
Is patient who has completed treatment, but who does not yet meet the criteria to be classified as 
cured or failures. 
2.8.10 Treatment failure 
Patient whose sputum smear is positive at five months, or later during treatment. 
2.8.11 Died 
A patient who, has died for any reason(s) during the course of treatment. 
2.8.12 Defaulter 
Are patients whose treatment was interrupted for 2 consecutive months or more. 
2.8.13 Transferred/moved out  
 
If a patient is transferred/moved to another facility to continue treatment the date of transfer 
needs to be entered, as well as where the patient must keep his/her original MDR/ extensive 
drug-resistant (XDR)-TB Registration Number and the final outcome must be referred back to 
the original MDR-TB unit. 
2.8.14 Treatment success 
The sum of patients cured and those who completed treatment. 
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2.9 Risk factors for tuberculosis 
Twin studies in the 1940s showed that susceptibility to TB was heritable. If one of a pair of twins 
contracted TB, then the other was more likely to get TB if he was identical than if he was not 
(www.angola.xn, 2007). Diet may also modulate risk. For example, among immigrants in 
London from the Indian subcontinent, vegetarian Hindu Asians were found to have an 8.5 fold 
increased risk of tuberculosis, compared to Muslim who ate meat and fish daily. Although a 
causal link is not proved by this data, this increased risk could be caused by micronutrient 
deficiencies: possibly iron, vitamin B12 or vitamin D (www.angola.xn, 2007). Diabetes mellitus 
is also an important risk factor that is growing in importance in developing countries (Strachan et 
al, 1995-2002). Persons with chronic renal failure and also those on haemodialysis have an 
increased risk, 10 to 26 times greater than the general population (www. en.Wikipedia.org, 
2007). Persons with silicosis have an approximately 30 times greater risk for developing TB 
(CDC, 2003). Along with overcrowding, poor nutrition may contribute to the strong link 
observed between tuberculosis and poverty (www.angola.xn, 2007). Further studies have 
provided more evidence of a link between vitamin D deficiency and an increased risk of 
contracting tuberculosis (Ustianowski, et al, 2005). 
Silica particles irritate the respiratory system, causing immunogenic responses such as 
phagocytosis, which, as a consequence, results in high lymphatic vessel deposits. Immuno-
compromised patients (30 – 40% of AIDS patients in the world also have TB) may have 
haematologic and reticuloendothelial diseases (www.angola.xn, 2007), such as leukemia and 
Hodgins’ disease, vitamin D deficiency (Nnoaham and Clarke, 2008) and low body weight 
(Kumar, 2007 and CDC, 2003). 
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Globally, severe malnutrition common in parts of the developing world causes a large increase in 
the risk of developing active tuberculosis, due to its damaging effects on the immune system 
(Schible and Kautmann, 2007 and Lonnroth and Raviglione, 2008). (www.angola.xn, 2007) 
prisoners, especially in poor countries, are particularly vulnerable to infectious disease such as 
HIV/AIDS and TB. Therefore, in addition to drug–drug interactions, drug–disease interactions 
and drug–nutrition/food interactions affecting treatment outcomes in patients, MDR-TB and HIV 
also affect the TB treatment outcomes (Kim DH et al, 2010). 
Other conditions that increase risk include the sharing of needles among intravenous drug users; 
recent TB infection or a history of inadequately treated TB; chest X-ray suggestive of previous 
TB, showing fibrotic lesions and nodules; prolonged corticosteroid therapy, and other 
immunosuppressive therapy.  These findings were more recently confirmed by a series of studies 
in South Africa (Jepson and Banya, 2001; Sepulveda, 1994 and Cobatt, 2010). There are 
“increasing drug resistance threatens gains of world TB programs, smoking and diabetes are also 
fuch” (such as HIV which increases risk more than 20-fold, poverty and over-crowding) 
(Alimuddin, 2011).  
2.10 The effects of multidrug-resistant tuberculosis on the human immunodeficiency 
virus epidemic 
The complete link between HIV and MDR-TB is not fully understood. Nevertheless, outbreaks 
of MDR-TB in HIV-infected patients have been associated with extraordinarily high mortality 
rate (www.Sahealthinfo.com, 2011). Human immunodeficiency virus patients also tends to have 
a higher rate of adverse drug reactions, notably peripheral neuropathy, cutaneous reactions, 
gastrointestinal disturbances, renal toxicity and neuropsychiatric effects (www.Sahealthinfo.com, 
2011).  Malabsorption of MDR-TB drugs has been reported in patients with HIV-related 
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enteropathology and dramatic impact of highly active antiretroviral therapy (HAART) on MDR-
TB mortality has been reported in co-infected patients (www.Sahealthinfo.com, 2011). 
The most potent risk factor for active disease, however, is impaired immunity, the risk increasing 
to 5 - 10% per year.  Although HIV is the most common reason for immune deficiency in South 
Africa, it should be kept in mind that impaired immunity can also result from malnutrition, 
congenital syndromes, haematological diseases, endocrine or renal disease and diabetes mellitus. 
Patients who are receiving immunosuppressive drugs or radiation therapy may also be at 
increased risk of active disease (www.Sahealthinfo.com, 2011). 
2.11 Treatment of multidrug resistant tuberculosis 
Treatment for TB uses antibiotics to kill bacteria. Effective TB treatment is difficult, due to the 
unusual structure and chemical composition of the mycobacterial cell wall, which makes many 
antibiotics ineffective and hinders the entry of drugs such as kanamycin, Ethionamide, 
ethambutol, ofloxacin, cycloserine and pyrazinamide (Acharya, 1967; Miglione et al 1966; 
Acharya and Goldman, 1970 and Brennan et al, 1995). The DOTs strategy of tuberculosis 
treatment is recommended by the WHO, based on clinical trials done in the 1970s by 
Tuberculosis Research Centre, Chennai, India. The country in which a person with TB lives can 
determine what treatment they receive. The reason for this is because MDR-TB is resistant to 
most first-line medications and the use of second-line anti-tuberculosis medications is necessary 
to cure the patient. However, the price of these medications is high; thus poor people in the 
developing world have no or limited access to these treatments (www.anlna.xn, 2007).  
The two antibiotics most commonly used are isoniazid and rifampicin. However, instead of the 
short course of antibiotics typically used to cure other bacterial infections, TB requires much 
longer periods of treatment (around 6 to 24 months) to entirely eliminate mycobacteria from the 
 
 
 
 
 
 
 
 
20 
 
body (www.boerner.net, 2007). Latent TB treatment usually uses a single antibiotic, while active 
TB disease is best treated with combinations of several antibiotics, to reduce the risk of the 
bacteria developing antibiotic resistance. People with latent infection are treated to prevent them 
from progressing to active TB disease later in life. 
Drug-resistant tuberculosis is transmitted in the same way as regular TB. Primary resistance 
occurs in persons infected with a resistant strain of TB. A patient with fully susceptible TB 
develops secondary resistance (acquired resistance) during TB therapy because of inadequate 
treatment, not taking the prescribed regimen appropriately, or using low-quality medication 
(www.boerner.net).  
The National TB program recommends first-line anti-tuberculosis treatment which includes 
rifampicin, isoniazid, ethambutol, pyrazinamide, and streptomycin. In South Africa, the 
guidelines for MDR-TB treatment have been drawn from the WHO guidelines. There are two 
regimen approaches, the first one is a standard treatment regimen and the second one is 
individualized treatment regimen (Weyer, 1999). The standard treatment regimen consists of 6 
months intensive phase with five drugs (ofloxacin, kanamycin, ethionamide, cycloserine, and 
para-aminosalicyclic acid (PAS) (www.Sahealthinfo.com, 2011) followed by a continuous phase 
of 18-24 months with 4 drugs (ethionamide, ofloxacin, pyrazinamide and cycloserine). The drugs 
used in the two phases and the dosages of these drugs are given in Table 2.1 and Table 2.2 
WHO, 2008; Department of Health, (National, 2006).  
Table 2.1: Second line antituberculosis drugs used in the intensive phase (6 months) in South 
Africa. WHO, 2008; Department of Health, (National, 2006). 
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Drug Daily Dosage  
 Average (mg/kg) Maximum (mg) 
Kanamycin 
Ethionamide 
Pyrazinamide 
Ofloxacin  
Cycloserine 
 
 
15 
10-20 
20-30 
7.5-15 
10-20 
 
1000 
1000 
1600 
800 
1000 
 
Table 2.2: Second line antituberculosis drugs used in the continuation phase (18-24 months) in 
South Africa 
 
Drug Daily Dosage Maximum (mg) 
 Average (mg/kg)  
Ethionamide 
Ofloxacin  
Pyrazinamide 
 
10-15 
7.5-15 
20-30 
 
1000 
800 
1500 
 
Drug Daily Dosage 
Average (mg/kg 
Maximum (mg) 
Cycloserine 10-29 1000 
Key: mg/kg=milligram/per kilogram 
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2.12 Classification of drugs for multidrug-resistant tuberculosis treatment in  
South Africa 
The treatment of MDR-TB patients was based on (D. falzon, 2011) drug sensitivity testing of 
second-line anti-TB drugs. These drugs have bactericidal or bacteriostatic properties. Drugs with 
moderate bactericidal activity: aminoglycosides, thionamides and, under acid ph conditions, 
pyrazinamide. Drugs with low bactericidal activity: fluoroquinolones, and drugs with 
bacteriostatic effect (www.tbrieder.org, ) when given at usual dosages in men: ethambutol, 
cycloserine and para-aminosalicylic acid (PAS). 
The ranking of drugs from high to moderate ranking for treatment of MDR-TB is presented in 
Table 2.3. Drugs should be selected from the higher ranking categories according to bacterial 
susceptibility. The initial regimen should consist of 5 drugs to which the bacilli has been shown 
to be susceptible (www.tbrieder.org, 2008). At least 3 of these drugs should not have been 
administered to the patient previously (that is, 3 months or more). Not more than 1 drug should 
be chosen from each of these categories in table 2 and all patients should receive an 
aminoglycoside during the intensive phase of treatment (Weyer et al, 1999). 
Apart from the acceptable daily dosages, other criteria should be considered; the effects of the 
drugs, patient tolerance and acceptability (for example, bulk or flume of drug to be injected, 
swallowed; taste and pain). This deals with the drugs, formulation, daily dosages, acceptable and 
main characteristics of antituberculosis drugs available for the treatment of MDR Tuberculosis 
(www.Sahealthinfo.com, 2011). The drugs are given in Table 2.4 Department of Health, 
(National, 2006). 
Irrespective of whether approach 1 or 2 is followed, certain essential management principles 
should be adhered to under all circumstances: directly observed therapy throughout the treatment 
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course is essential. The aim of treatment should be for 18-24 months of treatment always with an 
initial 6 months of intensive therapy. The continuation period may be shortened provided that 12 
months of treatment has been given after sputum conversion demonstrated by 3 consecutive 
negative monthly cultures. Establishing the HIV status is of clinical importance since HIV sero-
positive patients may suffer increased side-effects from antituberculosis drugs. When side effects 
occur that are not potentially life threatening, every effort should be made to coach patients 
through with palliation and psychological support. Drugs with known severe side effects should 
be given in divided doses to improve tolerance. Patients with severe side effects should be 
treated in hospitals Department of Health, (National, 2009). 
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Table 2.3: Ranking of drugs from 1 to 5 based on drug susceptibility testing used for treatment 
of multidrug-resistant tuberculosis in South Africa (WHO, 2008; National Department of Health, 
2006). 
  
 
Rank Drugs Average daily 
dosage 
Types of  
Activity 
Peak serum  
level (µg/ml) 
1 Aminoglycosides 
(a) Streptomycin 
(b) Kanamycin 
(c) Amikacin 
 
 
15mg/kg 
15mg/kg 
15mg/kg 
Bactericidal 
 
 
20-30 
5-75 
10-15 
 
2 Ethionamide 5-10mg/kg Bactericidal 2-4 
3 Pyrazinamide 20-30 Bactericidal  4-8 
4 Fluoroquinolones 
(a) Ofloxacin 
 
(b) Ciprofloxacin 
 
7.5-15mg/kg 
 
7.5-15mg/kg 
 
Weakly 
bactericidal 
Weakly 
bactericidal 
 
7.5-10 
 
2.5-5 
 
5 Cycloserine 5-10mg/kg Bacteriostatic 2-4 
 
 
 The table above shows, for each of the 2nd line anti-TB drugs, the dosage, the antibacterial  
activity (Cheuk-MT, 2009) and the peak plasma concentrations. 
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2.13 Pharmacology of the drugs used for the treatment of multidrug-resistant 
tuberculosis in South Africa  
The treatment of MDR-TB involves second line drugs which include an aminoglycoside 
(amikacin or kanamycin) (Mirsaeidt SM, 2005), a fluoroquinolone (ofloxacin or ciprofloxacin), 
a glycopeptides (capreomycin), a thiomide (ethionamide or prothionamide), cycloserine, 
ethambutol, para-aminosalicylic acid (PAS) and pyrazinamide (Tomioka, 2000; WHO, 2003; 
Perri and Bonora, 2004). Ethambutol and pyrazinamide are still used in patients where resistance 
to ethambutol and pyrazinamide is not confirmed. 
2.13.1 Pyrazinamide 
Pyrazinamide is active only against M. tuberculosis including M. bovis. And among the genus, 
mycobacteria are naturally resistant to pyrazinamide. The drug is largely bacteriostatic, but can 
be bacteriocidal as and when tuberculosis bacterium actively replicates itself. It was recognized 
early on that pyrazinamide acts only in an acid environment. The active derivative of 
pyrazinamide is pyrazinoic acid, which is preferentially accumulated in an acidic pH. 
Pyrazinamide as such is not active against intracellular growing M. tuberculosis. Only the 
accumulation of pyrazinoic acid through the action of the amidase pyrazinamidase by susceptible 
M. tuberculosis leads to its intracellular bactericidal action. The presence of both the 
pyrazinamidase and pyrazinamide-transport-system in M. tuberculosis has been postulated as 
prerequisites for drug susceptibility. 
 Pyrazinamide plays a unique role in shortening the therapy from previously 9–12 months to 6 
months, (Zhaung and Mitchson, 2003). It kills a population of semi-dormant tubercle bacilli in 
acidic pH environments that are not killed by other TB drugs (Mitchison 1995).  Pyrazinamide is 
a paradoxical and unconventional drug (Zhang and Mitchison 2003). Despite its remarkable 
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sterilizing activity in vivo (Grosset 1978). pyrazinamide is not active against Mycobacterium 
tuberculosis under ‘normal’ culture conditions near neutral pH.  Pyrazinamide is only active 
against M. tuberculosis at acid pH (Mc Dermott and Tompsett, 1954),  an environment that is 
produced during active inflammation, and its activity is closely related to the acidity of the 
medium (Salfinger and Heifets 1988); Even at acid pH (e.g. pH 5.6), pyrazinamide kills M. 
tuberculosis slowly and incompletely with no more than 76% of the bacterial population being 
killed by 1000 mg/L pyrazinamide (Heifets and Lindholm-L et al, 1990); which is 10–20 times 
higher than the already high minimum inhibitory concentration (MIC) of 50–100 mg/L (Zhang 
and Mitchison 2003). It has been shown that the acid pH requirement of pyrazinamide action is 
the result of increased accumulation of pyrazinoic acid (POA), the active form of pyrazinamide, 
in the tubercle bacilli at acid pH but not at neutral pH.  
After oral intake of 1500 mg of pyrazinamide, a peak level of 25 to 30 mg/L (Salfinger et al, 
1988) is achieved after one to one and a half hours. Pyrazinamide is well absorbed orally. 
Pyrazinamide has one of the best penetrations into cerebrospinal fluid among the anti-
tuberculosis medications. It crosses inflamed meninges and is an essential part of the treatment 
of tuberculous meningitis. Pyrazinamide is metabolized by the liver and the metabolic products 
are excreted by the kidneys. About four per cent of pyrazinamide is excreted unchanged in urine, 
and about 30% excreted as pyrazinoic acid. Pyrazinamide metabolism is only slightly influenced 
by ingestion of antacids, but, with a fatty meal, Tmax (drug peak time) is delayed and Cmax 
(maximum concentration of pyrazinamide) (www.atcl.ru, 2011) slightly lowered, though these 
effects are unlikely to bear clinical relevance. Absorption of pyrazinamide is not influenced by 
food intake. It has dosage of 25–39 mg/kg daily (www.atcl.ru, 2011). It has side effects by 
having two major adverse drug events of pyrazinamide are hepatotoxicity and interference with 
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the metabolism of purine. The latter leads to decreased excretion and to accumulation of uric 
acid, occasionally accompanied by gout-like arthralgia. The arthralgia can be distressing to 
patients, but is never harmful. The most dangerous side effect of pyrazinamide is hepatotoxicity, 
which is dose related. The present reduced recommended dose has significantly brought down 
the incidence of the side effect, hepatitis. In the standard four-drug regimen (isoniazid, 
rifampicin, pyrazinamide, and ethambutol), pyrazinamide is the most common cause of drug-
induced hepatitis. Other side effects include nausea and vomiting, anorexia, sideroblastic anemia, 
skin rash, urticaria, pruritus and hyperuricaemia (www.atcl.ru, 2011).  
The MICs of pyrazinamide (PZA) were determined for Mycobacterium tuberculosis cultivated 
under different pH conditions in 7H12 liquid medium. Mycobacterial growth was monitored by 
the radiometric method (BACTEC system; Johnston Laboratories, Inc., Towson, Md.). It has 
been predicted eightfold difference between the MICs determined at pH 5.5 and those 
determined at pH 5.95. The highest MICs for 21 susceptible strains were 50.0 micrograms/ml at 
pH 5.5 and 400 micrograms/ml at pH 5.95. This eightfold difference enabled us to predict MICs 
at pH 5.5 from the values observed at pH 5.95. The use of 7H12 broth at pH 5.95 simplified the 
radiometric PZA susceptibility test by avoiding the addition of acid solutions in the course of 
cultivation, which was required when the test was performed at pH 5.5. An additional benefit of 
using pH 5.95 instead of pH 5.5 was that all tested strains grew at pH 5.95, while some of them, 
especially PZA-resistant strains, did not grow at pH 5.5 (Salfinger et al, 1988). 
2.13.2 Ethambutol  
Ethambutol is a bacteriostatic, antimycobacterial drug prescribed to treat tuberculosis (Yan 
dapally et al 2008). It is usually given in combination with other tuberculosis drugs, such as 
isoniazid, rifampicin and pyrazinamide (www.absoluteastronomy.com, 2008). Ethambutol is 
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bacteriostatic against actively growing TB bacilli. It works by obstructing the formation of cell 
wall. Mycolic acids attach to the 5'-hydroxyl groups of D-arabinose residues of arabinogalactan 
and form mycolyl-arabinogalactan-peptidoglycan complex in the cell wall. It disrupts 
arabinogalactan synthesis by inhibiting the enzyme arabinosyl transferase. Disruption of the 
arabinogalactan synthesis inhibits the formation of this complex and leads to increased 
permeability of the cell wall. 
It is well-absorbed from GIT (gastrointestinal tract) with protein binding 20 to 30%. It has half-
life of 3-4 hrs (“E”, 2007) (increased in impaired renal function). It is well distributed, except to 
CSF, where 10-50% penetrates the inflamed meninges’ prolonged in renal failure. Up to 25% is 
metabolized in the liver. It is well absorbed from the GIT and well distributed in body tissues and 
fluids, 50% is excreted unchanged in urine (www.Vandvdevelopments). Elimination is mainly 
by excretion of unchanged drug in the urine (H. Mcilleron, 2009). Ethambutol is used during the 
intensive phase of standard retreatment regimen. In South Africa, the rate of acquired resistance 
to ethambutol is high, which has led to replacing with cycloserine. It has adverse effects like 
optic neuritis (Lim SA, 2006).  
The MIC were determined between MICs of ethambutol for both Mycobacterium avium and 
Mycobacterium tuberculosis strains by using broth dilution (7H12 broth, radiometric method) 
and agar dilution (7H11 agar) methods. It has been discovered that MIC’s to be much lower in 
liquid than in solid medium. The broth-determined MICs for susceptible M. tuberculosis and 
most of the M. avium strains were comparable to the levels in blood of patients, being lower than 
the peak levels. It has been proposed that the MICs, determined radiometrically in 7H12 broth, 
be considered as tentative criteria for susceptibility testing of M. avium isolates in future clinical 
trials. The use of these values instead of critical concentrations should also be considered as an 
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alternative to the conventional susceptibility testing method in chemotherapy of tuberculosis. 
Ethambutol produced bactericidal effects against both M. tuberculosis and M. avium, and the 
MIC/MBC ratios were in the same range for both species when MICs and MBCs were tested in 
7H12 broth by conventional sampling and plating (www.bionersonline.com, 2010). 
2.13.3 Kanamycin  
Kanamycin belongs to a group of drugs known as aminoglycosides which includes streptomycin, 
amikacin and so on. It has bactericidal activity against M. tuberculosis (Ho et al, 1997). 
Kanamycin is one of the second-line anti-TB agents (www. lrsitbrdruc.in, 2009) used and are 
clinically efficacious (Katherine MC et al, 2009). The potential for pharmacokinetic drug 
interactions is low, although additive toxicities may occur. The 16S rRNA from Escherichia coli 
is well studied among the rRNA subunits, and in particular, the interactions of various 
aminoglycoside antibiotics with the 16S rRNA and their effects on the process of translation of 
mRNA into polypeptide have been scrutinized (Noller, 1991).  
Similar rRNA structures exist in other organisms, such as yeast and Tetrahymena (LP. Kotra, 
2000). Treatment of rRNA with an aminoglycoside protects several nucleic bases in rRNA from 
chemical modification, implying that these molecules possess high affinities for certain sites in 
rRNA. This mode of binding was likened by (Noller, 1991) to that of enzyme inhibitors, which 
usually bind to the active sites of enzymes and interfere with their activities. Different classes of 
aminoglycoside antibiotics bind to different sites on the rRNA, depending on the structural 
complementarity between the two. For example, neomycin, paranomycin, gentamicin, and 
kanamycin are believed to bind to the A-site on the 16S rRNA in E. coli in a similar fashion and 
were shown to protect bases A1408 and G1494 in chemical foot printing experiments (www, 
intl-aac.usm.org, 2011). Four bases, A1408, A1492, A1493, and G1494, in the rRNA A-site 
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interact with tRNA, although with different affinities. The binding of the aforementioned 
aminoglycosides to the A-site in the decoding region (i.e., the site of codon and anticodon 
recognition) interferes with the accurate recognition of cognate tRNA by rRNA during 
translation (Noller, 1991). These interactions are also thought to interfere with the translocation 
of tRNA from the A-site to the peptidyl-tRNA site (P-site).  
Aminoglycosides achieve high concentrations in bone, pleural, synovial and peritoneal fluids and 
show poor CSF penetration (except amikacin in children with meningitis (Katherine MC et al, 
2009)). It is widely used in this study because of less toxicity when compare with other group. 
Kanamycin should not be administered with NRTI and tenofovir because it causes renal 
dysfunction. Aminoglycosides are ototoxic (Brummet et al, 1989).   
TEM-1 β-lactamase is a highly efficient enzyme that is involved in bacterial resistance against β-
lactam antibiotics such as penicillin. It is also a robust scaffold protein which can be engineered 
by molecular-evolution techniques to bind a variety of targets. One such β-lactamase variant 
(BlaKr) has been constructed to bind kanamycin (kan) and other aminoglycoside antibiotics, 
which are neither substrates nor ligands of native β-lactamases. In addition to recognizing kan, 
BlaKr activity is up-regulated by its binding via an activation mechanism which is not yet 
understood at the molecular level. In order to fill this gap, determination of the structure of the 
BlaKr-kan complex was embarked upon. A crystallization condition for BlaKr-kan was 
identified using high-throughput screening, and crystal growth was further optimized using 
streak-seeding and hanging-drop methods. The crystals belonged to the orthorhombic space 
group (Karen Van dewater et al, 2011) P2 (1)2(1)2(1), with unit-cell parameters a = 47.01, b = 
72.33, c = 74.62 Å, and diffracted to 1.67 Å resolution using synchrotron radiation. The X-ray 
structure of BlaKr with its ligand kanamycin should provide the molecular-level details 
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necessary for understanding the activation mechanism of the engineered enzyme (Karen et al, 
2011).  
Kanamycin is given intravenously or intramuscularly at a dose of 15mg/kg per min in two or 
three divided doses, with a dose reduction in renal impairment. It is also excreted rapidly by 
glomerular filtration with a serum half-life of about 4hr. Therapeutic drug monitoring may be 
useful, aiming for Cmax of 15-30µg/ml and Ctrough (Katherine MC et al, 2009) (area under the 
momentum curve from zero to infinity) of less than 10µg/ml (A. Tampuz, 2008). Previous 
studies have demonstrated that exposure to sublethal levels of kanamycin antibiotic increased the 
capsular polysaccharide production by Escherichia coli B23 cells. The capsular polysaccharides 
were associated with resistance against antibiotics. This study attempted to investigate whether 
an interaction exists between the antibiotic and either isolated capsular polysaccharide or isolated 
soluble polysaccharide to assess a direct relationship between antibiotic insensitivity and 
capsular polysaccharides. Three types of polysaccharides including capsular polysaccharides 
obtained from Escherichia coli B23 grown with or without kanamycin pre-treatment and soluble 
capsular polysaccharide secreted by Escherichia coli K1-K12 hybrid EV36 were mixed with 
kanamycin and these samples were used for the MIC assay, kanamycin sensitivity test and the 
Kirby-Bauer (KB) assay. 
 It was found that the addition of polysaccharides did not have a significant effect on either the 
growth of cells or the MIC of kanamycin while all three types of polysaccharides provided 
protection against low concentrations of kanamycin observed in the kanamycin sensitivity tests. 
In the KB assay, filter disks containing 20 μg/ml and 10 μg/ml of kanamycin near the filter disks 
of the capsular polysaccharide from cells with kanamycin pre-treatment showed smaller and 
inward distorted shaped inhibition zones, while the disks of the same kanamycin concentrations 
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near the disks of the capsular polysaccharide from cells grown without kanamycin pre-treatment 
had normal zones. The difference in the degree of protection observed against exposure to low 
concentrations of kanamycin between the two types of capsular polysaccharides could not be 
determined (Park et al, 2007).  
2.13.4 Ethionamide  
Ethionamide belongs to a group of drugs known as thioamides. Ethionamide is administered 
orally with a bioavailability of over 90% (Katherine MC et al, 2009). It is started at 250mg daily. 
The dose is titrated up to 15-20mg/kg per day (maximum 1 g daily) if gastric irritation permits. It 
is usually given once daily but divided doses can lessen gastrointestinal symptoms. It reaches 
high concentration throughout the body including in CSF; and 10-30% is protein bound 
(Katherine MC et al, 2009).  
The side effects associated with tuberculosis therapy bring with them the risk of noncompliance 
and subsequent drug resistance. Increasing the therapeutic index of antituberculosis drugs should 
thus improve treatment effectiveness. Several antituberculosis compounds require in situ 
metabolic activation to become inhibitory. Various thiocarbamide-containing drugs, including 
ethionamide, are activated by the mycobacterial monooxygenase EthA, the production of which 
is controlled by the transcriptional repressor EthR. Here we identify drug-like inhibitors of EthR 
that boost the bioactivation of ethionamide. Compounds designed and screened for their capacity 
to inhibit EthR-DNA interaction were co-crystallized with EthR. We exploited the three-
dimensional structures of the complexes for the synthesis of improved analogs that boosted the 
ethionamide potency in culture more than tenfold. In Mycobacterium tuberculosis–infected mice, 
one of these analogs, BDM31343, enabled a substantially reduced dose of ethionamide to lessen 
the mycobacterial load as efficiently as the conventional higher-dose treatment. This provides 
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proof of concept that inhibiting EthR improves the therapeutic index of thiocarbamide 
derivatives, which should prompt reconsideration of their use as first-line drugs (www. 
lib.bioinfo.pl, 1984). 
Ethionamide is metabolized in the liver to seven metabolites, some of which are biologically 
active. Metabolism occurs by sulphoxidation, desulphuration and deamination, followed by 
methylation (Jenner et al, 1984, Berning et al, 1998). The involvement of CYP450 enzymes 
means that drug interactions are likely. Less than 1% is excreted unchanged by the kidneys. 
Therapeutic drug monitoring is recommended in hepatic impairment. A high incidence of 
hepatotoxicity has been reported when Ethionamide has been used with other hepatotoxicity 
drugs such as rifampicin (Katherine MC et al, 2009). Blood tests were taken during treatment to 
detect side effects of ethionamide and rifampicin on the liver of the patients. Caution should 
therefore be exercised if co-prescribed antiretroviral which have been strongly associated with 
abnormal liver function, including the NNRTIs efavirenz and nevirapine (Bruck et al, 2008). 
Blood tests were also taken for toxicity of drugs on the patients.  
Ethionamide can cause depression, anxiety and psychosis. It may therefore not be advisable to 
start efavirenz at the same time, since these side effects are commonly experienced in the first 
weeks of efavirenz therapy (Katherine MC et al, 2009). Blood tests were also taken for toxicity. 
A psychotic reaction has been reported with the combination of ethionamide and excess alcohol 
(Lansdown et al, 1967). It has been reported that patients experience antabuse when alcohol is 
taken with alcohol. Patients should therefore be counseled to avoid excess alcohol. Neurotoxic 
effects can be prevented by giving pyridoxine 200mg daily. 
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2.13.5 Ofloxacin  
Ofloxacin belongs to a group of drugs known as fluoroquinoles (FQNs). There are broad-
spectrum antibiotics and tuberculocidal. It demonstrated the activity of fluoroquinoles (FQNs) 
within human macrophage, where many tubercle bacilli reside (Katherine MC et al, 2009). Their 
mechanism of action is inhibition of bacterial topo-isomerase IV and DNA gyrase enzymes 
required for bacterial DNA replication, transcription, repair and recombination. There is no 
substantial loss from first-pass metabolism. Oral bioavailability of 98% and with a peak serum 
concentration reached within 1-2 hours (Ziganshina et al, 2005).  
The absorption of all FQN is reduced by buffered drugs including older formulations of 
didanosine, and they should be taken 2 hr before or 6 hr after any buffered drugs. They can also 
be administered intravenously. Binding to plasma proteins is moderate 20-50% (Katherine MC, 
2009). It is included because of its high protein-binding but not high enough to have significant 
interactions with protein binding of other drugs.  
Levofloxacin is the optical S- (-) isomer of ofloxacin and is twice as potent in vitro (Katherine 
MC et al, 2009). Ofloxacin is widely distributed in body fluids, and penetrates CSF better than 
levofloxacin. Dose reduction is required in renal failure and caution should be exercised when 
co-prescribed drugs associated with renal dysfunction including tenofovir. Only 4-8% of the 
dose is recovered from the feces (Katherine MC et al, 2009). Many in vitro studies reported that 
ofloxacin has relatively potent activity against MTB and other species of mycobacteria for 
example, Mycobacterium kansasii and Mycobacterium avium complex (Vacher et al, 1999). 
Ofloxacin is active against drug resistant Mycobacterium tuberculosis with 2µg/ml as a 
minimum inhibitory concentration for 90% (MIC90) of tested stains, other studies demonstrated 
that activity of fluoroquinoles including ofloxacin within human macrophage, where many 
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tubercule bacilli reside (Wise and Honeybourne, 1999, Ruiz-Serrano et al, 2000). In addition, the 
antituberculosis effects of low, non-bactericidal concentration of ofloxacin within the 
macrophage is enhanced by the presence of PZA, which is important for the use of these agents 
in TB preventative combination regimens (Jacobs, 1999. Berning, 2001).  
2.13.6 Cycloserine / Terizidone  
Cycloserine or terizadone is obtained by combining two molecules of cycloserine and one 
molecule of terephtalaldehyde and is a broad spectrum antibiotic which greatly improved the 
disadvantages associated with Cycloserine. Terizidone has potent and extended 
antimycobacterial activities, and exerts remarkable effects against not only strains causing 
pulmonary tuberculosis or urinary tract infections but also strains which have become resistant to 
existing antimycobacterial drugs (www. japi.org, 2009). 
Its mode of action is similar to cycloserine that is, it acts by inhibiting cell wall synthesis by 
competitively inhibiting two enzymes, L-alanine racemase and D-alanine ligase, thereby 
impairing peptidoglycan formation necessary for bacterial cell wall synthesis. Although, being 
broad spectrum, the molecule in principle active against other bacteria as well, terizidone is not 
recommended for use in the treatment of infections other than tuberculosis (www, japi.org, 
2009). Terizadone is readily and almost completely absorbed from the GIT. Plasma protein 
binding is less than 20%. It is widely distributed throughout body fluids including CSF 
(Katherine MC et al, 2009).  
It is probably advisable not to start efavirenz concurrently because CNS side effects may be 
worsened by concomitant use of psychoactive drugs or alcohol. 
It is readily absorbed widely distributed to tissues and fluids including CSF (H. Mcillron, 2009). 
Cycloserine is bacteriostatic in the usual dosage. It is a valuable companion drug to prevent 
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resistance to other second-line drugs, since it does not share cross-resistance with other active 
TB drugs. It has a high incidence of side effects. Terizidone is obtained by combining two 
molecules of cycloserine and one molecule of terephtalaldehyde ans is a broad spectrum 
antibiotics which greatly improved the disadvantages associated with cycloserine. Its mode of 
action is similar to cycloserine that is, it acts by inhibiting cell wall synthesis by competitively 
inhibiting two enzymes, L-alanine racemase and D- alanine ligase, thereby impairing 
peptidoglycan formation necessary for bacterial cell wall synthesis (www. japi.org, 2009).  
The MICs of Terizidone for susceptible strains are 4-130 mg/ml. Terizidone is completely and 
rapidly absorbed after oral administration. Maximum concentration in blood are achieved in 
2 to 4 hours. It was noted that the blood concentration of terizidone was higher at all time 
intervals than the concentration attained in the blood after the same doses of Cycloserine. 
Excretion in urine is quicker in the young ones. Its concentration in the urine after 30 hr 
administration sufficiently exceeded its minimum inhibitory concentration. This justifies its use 
in the treatment of urogenital TB. It was found that the increase in the dose does not cause a 
proportional increase in the concentration of the drug in the blood. It is well distributed in all 
body fluids and tissues. 
The half-life of terizidone was significantly greater than that of cycloserine with doses of 250 mg 
and 500 mg. Also, it was significantly higher in the elderly than the young patients. The 
molecule does not have cumulative toxicity and hence better tolerability (www.japi.org, 2009). 
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2.13.7 Para-aminosalicyclic acid  
Para-aminosalicyclic acid (also known as aminosalicyclic acid)  is bacteriostatic and active 
against M. tuberculosis. Other mycobacteria are usually resistant. It prevents plate biosynthesis 
in sensitive organisms. It has a relatively weak action compared with other anti-TB drugs and 
resistance may develop quickly if it is used alone, however it is still sometimes used in multi-
drug resistant tuberculosis in combination with other anti-TB drugs (Mathas D, 2009). 
It is readily absorbed (>90%); peak plasma concentration after oral dosing: 1-4 hours. Time to 
peak, serum: 6 hours. It diffuses into most body tissues and fluids (including breast milk) except 
CSF (unless meninges inflamed). Plasma protein binding: sodium salt: 15%; acid: 50-70%. It is 
metabolised both intestinally and hepatically (>50%) mainly by acetylation. It is excreted via 
urine: ≥80% dose within 24 hr (50% as acetylated metabolite). Half-life: approx 1 hr (reduced in 
renal impairment) (www.mims.com/USA, 2012).  
The MICs of all the clinical strains and spontaneous mutants were determined by the agar 
dilution method and BacT/Alert 3D system (bioMérieux, France). Briefly, samples (107 CFU/ml; 
diluted 1:100; 100 μl plated) were plated simultaneously on 7H11 plates containing 0, 16, 32, 64, 
and 128 μg/ml of PAS (D. Mathas, 2009), and the colony formation was tabulated. Likewise, 
MICs were determined using the BacT/Alert 3D system as recommended by the supplier. 
Finally, bacillary growth was monitored spectrophotometrically (optical density at 600 nm) 
every 72 hours for 32 consecutive days in triplicate. Growth curves were determined for four to 
six strains per group, including clinical isolates (n = 6), spontaneous mutants with an early stop 
codon in the thyA gene (n = 2) or with other mutations within the thyA gene (n = 6), and PASr 
isolates including wild-type genes in the folate and pyrimidine biosynthesis pathway (n = 6). 
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Growth curves were done on 7H9 broth in the presence of 0, 16, 32, 64, and 128 μg/ml of PAS. 
(www. ncbi.nlm.gov, 2011). 
Para-aminosalicyclic acid does not penetrate CSF unless the meninges are inflamed, in which 
case CSF concentration reach 10-50% of plasma concentrations (Katherine MC et al, 2008). It 
completely blocks absorption of B12 and can induce a malabsorption syndrome (Katherine MC 
et al, 2009). It is one of the side effects of PAS, yet is being used. 
Para-aminosalicyclic acid is rapidly acetylated in the liver and then excreted by glomerular 
filtration (Katherine MC et al, 2009). It is 80% excreted into urine, with 50% excreted in the 
inactive acetylated form. Approximately 50-70% of PAS is protein bound and the plasma half-
life is 45-60 min (Katherine MC et al, 2009). No interactions with antiretroviral agents have been 
described. 
2.14 The South African antiretroviral treatment guidelines 
The specific objectives for using ART is to prioritise ARVs for patients with CD4 counts < 200 
cells/mm3 or with severe HIV disease irrespective of CD4 count. The use of ARVs is for 
patients co-infected with TB/HIV. The use of ARVs is also for pregnant women with CD4 ≤ 350 
cells/mm3 for lifelong ART and CD4 > 350 cells/mm3 for prophylaxis. The use of stavudine 
must be reduced; to enable nurses to initiate ARVs for treatment and prevention and to enable 
primary health care (PHC) facilities to initiate, manage, monitor and refer patients for (Lawrence 
L, 2011) further management. The drugs used are given in Table 2.4 and Table 2.5 Department 
of Health (National, 2010). 
However, there is an amendment to the South African Antiretroviral Treatment Guidelines 2010. 
The Western Cape Department of Health (WCDOH) has started giving ARVs to all HIV positive 
patients, with CD4 ≤ 350cells/ml Department of Health (Provincial, 2011). 
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2.15 Pharmacology of first-line antiretroviral drugs 
The first-line antiretroviral drugs that were used during the course of study are: (1) Stavudine. (2) 
Lamivudine. (3) Efavirenz. However, Stavudine has been replaced with Tenofovir. 
2.15.1 Stavudine  
 It has been reported that stavudine has high renal toxicity and more side effects than tenofovir; 
while tenofovir is associated with fewer side –effects compared to AZT (Bygrave H et al, 2011). 
Stavudine is a nucleoside analogue of thymidine, is phosphorylated by cellular kinases to the 
active metabolite Stavudine triphosphate. Stavudine triophosphate inhibits the activity of HIV-1 
reverse transcriptase (RT) by competing with the natural substrate thymidine triophosphate 
(Ki=0.0083 to 0.032µm) and by causing DNA chain termination following its incorporation into 
viral DNA (www. packageinserts.bms.com, 2011). Stavudine triophophate inhibits cellular DNA 
polymerases ᵝ and ᵞ and markedly reduces the synthesis of mitochondrial DNA. The cell culture 
antiviral activity of Stavudine was measured in peripheral blood mononuclear cells, and 
lymphoblastoid cell lines. The concentration of drug necessary to inhibit HIV-1 replication by 
50% (EC50) ranged from 0.009 to 4µM against laboratory and clinical isolated of HIV-1. In cell 
culture, Stavudine exhibited additive to antagonistic activity in combination with zidovudine. 
Stavudine in combination with either abacavir, Didanosine, tenofirvir, or zalcitabine exhibited 
additive to synergistic anti-HIV-1 activity (www. packageinserts.bms.com, 2011). The 
relationships between cell culture susceptibility to stavudine have been selected in cell culture 
(strain-specific) and were also obtained from patients treated with stavudine. Phenotypic analysis 
of HIV-1 isolates from 61 patients receiving prolonged (6-29 months) stavudine monotherapy 
showed that post-therapy isolates from patients exhibited EC50 values more the 4-fold (range 7- 
16 fold) higher than average pre-treatment susceptibility of baseline isolates. The genetic basis 
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for Stavudine susceptibility changes has not been identified. Cross-resistance among HIV-1 
reverse transcriptase inhibitors has been observed. Several studies have demonstrated that 
prolonged Stavudine treatment can select and or maintain mutations associated with zidovudine 
resistance (www. packageinserts.bms.com, 2011). The pharmacokinetics of Stavudine has been 
evaluated in HIV-infected adult and pediatric patients. Peak plasma concentration (Cmax) and 
area under the plasma concentration-time curve (AUC) increased in proportion to dose after both 
single and multiple doses ranging from 0.03 to 4 mg/kg. There was no significant accumulation 
of Stavudine with repeated administration every 6, 8, or 12 hours. Following oral administration, 
Stavudine is rapidly absorbed, with peak plasma concentrations occurring within 1 hour after 
dosing. The systemic exposure to Stavudine is the same following administration as capsules or 
solution. Binding of Stavudine distributes equally between red blood cells and plasma. 
Metabolism plays a limited role in the clearance of stavudine (www.squibb.com, 2011). 
Unchanged Stavudine was the major drug-related component circulating in plasma after an 80mg 
dose of 14C-stavudine, while metabolites constituted minor components of the circulating 
radioactivity. Minor metabolites include oxidized Stavudine, glucuronide conjugates of 
Stavudine and its oxidized metabolite, and an N-acetylcysteine conjugate of the ribose after 
glycosidic cleavage, suggesting that thymine is also a metabolite of Stavudine.   
Following an ingestion of 80 mg radioactive, the result showed 73.7% of urine and 62% of feces 
respectively. The mean elimination half-life is approximately 2.3 hours following single doses. 
Mean renal clearance of the parent compound is approximately 272ml/min, accounting for 
approximately 67% of the apparent oral clearance. In HIV-infected patients, renal elimination of 
unchanged drug accounts for about 40% of the overall (www.packageinserts.bms.com, 2011). 
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Stavudine does not inhibit major cytochrome P450 isoforms CYP1A2, CYP2C9, CY2C19, 
CYP2D6, and CYP3A4; therefore, it is unlikely that clinically significant drug-interactions will 
occur with drugs metabolized through pathways. Stavudine is not protein-bound; it is not 
expected to affect the pharmacokinetics protein-bound drugs. 
However, fatal lactic acidosis has been occurred in patients treated with zerit® combination with 
other antiretroviral agents. If motor weakness develops, zerit® should be discontinued. Zerit® 
therapy has also been associated with peripheral sensory neuropathy, which can be severe, is 
dose related. And occurs more frequently in patients being treated with other drugs that have 
been associated with neuropathy (including Didanosine), in patients with advanced HIV 
infection, or in patients who have previously experienced peripheral neuropathy 
(www.squibb.com, 2011).  It has been suggested that stavudine should be stop if any of these 
signs of an allergic reaction occurs such as: hives, difficulty breathing; swelling of face, lips, 
tongue or throat. Other serious side effects includes liver damage- nausea, stomach pain, low 
fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); 
lactic acidosis-muscle pain or weakness, numb or cold feeling in arms and legs, trouble 
breathing, nausea with stavudine (www. Kids.sutterhealth.org, 2011).  
2.15.2 Lamivudine  
Lamivudine is an analogue of cytidine. It can inhibit both types (1 and 2) of HIV reverse 
transcriptase and also the reverse transcriptase of hepatitis B. It is phosphorylated to active 
metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse 
transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of 
a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' 
phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth 
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is terminated. Lamivudine is administered orally, and it is rapidly absorbed with a bio-
availability of over 80% (www.Vand developments, 2011).  
Some research suggests that lamivudine can cross the blood-brain barrier. Lamivudine is often 
given in combination with zidovudine, with which it is highly synergistic. Lamivudine treatment 
has been shown to restore zidovudine sensitivity of previously resistant HIV. Lamivudine 
showed no evidence of carcinogenicity or mutagenicity in vivo studies in mice and rats at doses 
from 10 to 58 times those used in humans (www.Vandvdevelopments, 2011). Lamivudine 
tablets, capsules, and oral solution dosage forms are bioequivalent. Protein binding is less than 
36%. Approximately 5% is recovered in the urine as a transsulfoxide metabolite and 70% is 
excreted unchanged in the urine. Active tubular secretion appears to play a role in the clearance. 
The most common side effects are nausea, diarrhoea and headache. Peripheral neuropathy, 
myalgias, pancreatitis, and lactic acidosis occur infrequently. In drug interactions with 
Zalcitabine, lamivudine and zalcitabine may result in mutual inhibition of intracellular 
Phosphorylation (www.antimicrobe.org/drugpopup/Lamivudine.pdf, 2011). Stop using 
lamivudine and get emergency medical help if you have any of these signs of an allergic 
reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Other serious 
side effects: liver damage - nausea, stomach pain, low fever, loss of appetite, dark urine, clay-
colored stools, jaundice (yellowing of the skin or eyes); lactic acidosis - muscle pain or 
weakness, numb or cold feeling in your arms and legs, trouble breathing, nausea with vomiting, 
and fast or uneven heart rate; pancreatitis - severe pain in your upper stomach spreading to your 
back, nausea and vomiting, fast heart rate; peripheral neuropathy - numbness, tingling, or pain in 
your hands or feet; easy bruising or bleeding, unusual weakness, pale skin; white patches or 
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sores inside your mouth or on your lips; fever, chills, body aches, flu symptoms; or any other 
signs of new infection. Less serious side effects may include: cough; sleep problems (insomnia), 
strange dreams; nausea, vomiting, diarrhea; joint or muscle pain; dizziness, headache, tired 
feeling; or changes in the shape or location of body fat (especially in your arms, legs, face, neck, 
breasts, and trunk). (www. Kids.sufferhealth.org, 2011). 
2.15.3 Efavirenz®  
Efavirenz® is a selective non-nucleoside reverse transcriptase inhibitor (NNRTI) of human 
 immunodeficiency virus type 1 HIV-1. Efavirenz ® diffuses into the cell where it binds adjacent 
to the active site of reverse transcriptase. This produces a conformational change in the enzyme 
and inhibits its function. Efavirenz ® is a noncompetitive inhibitor of HIV-1 reverse 
transcriptase (RT) with respect to template, primer or nucleoside triphosphates, with a small 
component of competitive inhibition. HIV-2 RT and human cellular DNA polymerases alpha, 
beta, gamma and delta are not inhibited by concentrations of efavirenz® 
(www.home.intekon.com, 2011). 
Peak efavirenz® plasma concentrations of 1, 6 –9, 1 microM were attained by 5 hours following 
 single oral doses of 100 mg to 1600 mg administered to uninfected volunteers. Dose-related  
increases in Cmax and AUC were seen for doses up to 1600 mg; the increases were less than 
 proportional suggesting diminished absorption at higher doses. Steady state plasma 
 concentrations are reached in 6 –7 days. Efavirenz ® is very highly bound (approximately 99,5 
–99,75%) to human plasma proteins, predominantly albumin. In HIV-1 infected patients 
 who  received efavirenz® 200 to 600 mg once daily for at least one month, cerebrospinal fluid 
 concentrations ranged from 0,26 to 1,19% (mean 0,69%) of the corresponding plasma 
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 concentration. This proportion is approximately three-fold higher than the nonprotein-bound  
(free) fraction of efavirenz in plasma. Efavirenz ® is principally metabolised by the cytochrome  
P450 system to hydroxylated metabolites with subsequent glucuronidation of these hydroxylated 
 metabolites. These metabolites are inactive against HIV-1. CYP3A4 and CYP2B6 are the major  
isozymes responsible for efavirenz® metabolism. Efavirenz ® has been shown to induce P450 
 enzymes, resulting in the induction of its own metabolism. Efavirenz ® has a long terminal half- 
life of 52 to 76 hours after single doses, and 40 –55 hours after multiple doses. Approximately 14 
 –34% of a radiolabelled dose of efavirenz was recovered in the urine and 16–61% was  
recovered in faeces, mainly in the form of metabolites.    
In drug interactions, aspen efavirenz ® is an inducer of CYP3A4. Other compounds that are  
substrates of CYP3A4 may have decreased plasma concentrations when co-administered with  
aspen efavirenz ®. When indinavir (800 mg every 8 hours) was given with 
aspen efavirenz ® (200 mg every 24 hours), the indinavir AUC and Ctrough were decreased 
 by approximately 31% and 16% respectively, as a result of enzyme induction. Therefore, the  
dose of indinavir should be increased from 800 mg to 1000 mg every 8 hours when aspen  
efavirenz ® and indinavir are co-administered. No adjustment of the dose of aspen efavirenz ® is 
 necessary when given with indinavir. When aspen efavirenz ® 600 mg (given once 
 daily at bedtime) and ritonavir 500 mg (given every 12 hours) were studied in infected 
volunteers, the combination was not well tolerated and was associated with a higher 
 frequency of adverse clinical experiences (for example, dizziness, nausea, paraesthesia and  
elevated liver enzymes occurred). When saquinavir (1,200 mg given 3 times a 
 day, soft capsule formulation) was given with aspen efavirenz ® the saquinavir AUC and  
Cmax were decreased by 62% and 50% respectively. Use of aspen efavirenz ® in combination  
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with saquinavir as the sole PI is not recommended. Rifampicin reduced aspen efavirenz 
 AUC by 26% and Cmax by 20% in 12 uninfected volunteers. The dose of efavirenz® must be  
increased to 800 mg/day when taken with rifampicin. No dose adjustment of rifampicin is  
recommended when given with aspen efavirenz®. The clinical significance of these  
change in clarithromycin plasma levels is not known. Co-administration of aspen  
efavirenz ® with methadone, in HIV-infected IV drug users, resulted in decreased plasma levels  
of methadone and signs of opiate withdrawal (www.adcock.co.za, 2011).    
Patients on aspen efavirenz ® should not concomitantly use products containing St. John’s Wort  
(Hypericum perforatum) since it may be expected to result in reduced plasma concentrations of  
aspen efavirenz ®. This effect is due to an induction of CYP3A4 and may result in loss of  
therapeutic effect and development of resistance. Aspen efavirenz ® does not bind to  
cannabinoid receptors (www.home.intekon.com, 2011). 
  The common side effects include abnormal dreams; diarrhea; dizziness; drowsiness; headache; 
 nausea; tiredness; trouble concentrating; trouble sleeping; upset stomach; vomiting. 
The following side effects are founds with patients when using efavirenz which include: Severe 
allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the 
mouth, face, lips, or tongue); burning, numbness, or tingling; change in personality; confusion; 
cough; delusions; fainting; fever, chills, or persistent sore throat; hallucinations; irregular 
heartbeat; memory loss; mental, mood, or behavior changes (for example, abnormal thoughts, 
agitation, aggression, anxiety, depression, nervousness, paranoia); mouth sores; rash with or 
without fever; red, swollen, blistered, or peeling skin; seizures; severe or persistent tiredness or 
weakness; severe stomach pain; shortness of breath; suicidal thoughts or behaviors; symptoms of 
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liver problems (for example, dark urine, loss of appetite, pale stools, yellowing of the skin or 
eyes); vision changes (www.drugs.com/sfx/efavirenz. 2011). 
2.16 Antituberculosis agents side effects  
Antiretrovirals (ARVs) are important for the treatment of HIV (+) patients and second-line anti-
TB drugs are used for MDR- TB in patients. The restoration of immune function is necessary for 
a successful therapeutic response (Gandhi et al, 2010). Studies show that there were drug 
interactions between anti-TB and HIV drugs. These drugs have additive toxicities of second-line 
anti-TB drugs (SLDs) and ARV therapy on the patients. The cumulative toxicities of these drugs 
include peripheral neuropathy with nucleoside reverse transcriptase inhibitors and 
aminoglycosides, neuropsychiatric toxicity with efavirenz and cycloserine and gastrointestinal 
intolerance with many ARV and SLDs. The drugs are given in Table 2.4 (Fried land, 2007 and 
WHO, 2006). The effects drug interactions in this study show poor MDR-TB treatment 
outcomes. 
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Table 2.4: Antituberculosis agents’ side effects 
 
(Friedland, 2007 and WHO, 2006). 
 
Diseases Drugs interactions 
Hepatitis Interactions with following drugs: 
Nevirapine, ritonavir- boosted protease, 
Isoniazid, rifampicin and Pyrazinamide show 
hypersensitivity reaction as side effects 
Gastrointestinal distress All antiretroviral with Ethionamide, 
Fluoroquinolones, Para-aminosalicyclic acid 
causes gastrointestinal intolerance but less 
common with Lamivudine and emtricitabine. 
Nephrotoxicity Tenofovir (renal tubular dysfunction, 
idinavir-ritonavir, streptomycin- 
Aminoglycosides (nephrotoxic TB agents 
carry particular risk of potentiating lactic 
acidosis common to the NRTIs used in 
antiretroviral roll-out regimens). 
Neuropsychiatric disorder Efavirenz (insomnia, drowsiness, vivid 
dreams), cycloserine (headaches, tremor, 
seizure), terizadone (mainly headache and 
seizures) 
Peripheral Neuropathy The side effects of the following: stavudine, 
Didanosine, cycloserine, streptomycin, 
aminoglycosides, isoniazid causes 
nephrotoxicity.  
 
Key:  
TB= Tuberculosis; NRTIs= Nucleoside reverse transcriptase inhibitors. 
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2.17 Interaction between antituberculosis and antiretroviral drugs 
Multidrug-resistant tuberculosis treatment is complicated and frequently associated with 
treatment failure, relapse and high incidences of adverse drug reactions, which lead to prolonged 
illness, disability and death as a consequence (Cohn, 1995; Flament-Saillour et al, 1999). 
Treatment of MDR-TB in patients co-infected with HIV (Gerald F, 2007) is associated with poor 
outcomes and high mortality rates of 72-89% (Cohn, 1995). Deaths during treatment caused by 
MDR-TB infection or by other HIV-related diseases are more frequent, particularly, in the 
advanced HIV-infection stages (www.stoptb.com 2003). This could be due to IRIS before the 
commencement of ARVs. It could also be caused by drug interaction between ARVs and anti-
TB drugs. However, starting treatment early may increase the survival time in HIV patient co-
infected with MDR-TB (Martins B, 2007). By contrast, HIV-negative patients with MDR-TB 
(Jacobs RF, 1996) have good response to appropriate MDR-TB chemotherapy regimens with 
64% outcomes of completing the course of therapy and no relapse (Telzak et al, 1995; Kwon et 
al. 2008). 
Immuno-compromised patients are at a high risk of drug (CE. French, 2008)-drug interactions 
during their TB treatment. This is due to lowered immune system. Outbreaks of multidrug-
resistant tuberculosis among HIV-infected patients have been documented since the 1980s. 
Recently, an outbreak of highly-lethal multidrug-resistant tuberculosis was discovered in South 
Africa, primarily involving HIV-infected patients (www. pubichealth.cacountry.gov, 2008). The 
link between this outbreak and drug interactions was due to inadequate TB treatment and poor 
drug sensitivity test in these patients. Prompt initiation of antiretroviral therapy may be one way 
to decrease the alarmingly high death rate among HIV-infected patients with multidrug-resistant 
tuberculosis. By doing so, would reduce morbidity and mortality. 
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Most of the “second-line drugs” ( fluoroquinolone antibiotics, ethionamide, cycloserine, 
kanamycin, amikacin, capreomycin, para-amino salicylate) were developed and approved nearly 
40 years ago, prior to the development of modern laboratory techniques to determine pathways 
of drug metabolism. Furthermore, there are no published studies of possible drug-drug 
interactions (Weyer, 2005); between second-line antituberculosis drugs and antiretroviral drugs. 
Based on the existing, albeit incomplete, knowledge of the metabolism of the second-line drugs, 
only ethionamide has a significant possibility of an interaction with antiretroviral drugs 
(www.cdc.gov, 2003). Ethionamide is thought to be metabolized by the CYP450 system, though 
it is not known which of the CYP isozymes are responsible. However, there are drug interactions 
with other second line anti-TB drugs (www.cdph.ca.gov, 2003).  
Stavudine ® and ethionamide causes peripheral neuropathy. Tenofovir and protease inhibitors 
(Lopinavir-ritonavir) causes increased tenofovir plasma levels. Efavirenz ® and protease 
inhibitors cause decreased efavirenz plasma levels. Ethambutol and pyrazinamide causes 
potential elevation of urate by pyrazinamide. Amikacin causes increased risk of oto- or 
nephrontoxicity. Ofloxacin inhibit hepatic microsomal enzymes. Ethionamide and cycloserine 
and terizadone causes increased risk of CNS (central nervous system) toxicity. Zidovudine has 
no drug interaction (South African Medicines Formulary, 2010). In conclusion, the proper 
management of MDR-TB and HIV patients needs to be understood for (Kent S, 2010) better 
treatment outcomes. Multidrug-resistant tuberculosis treatment is complicated and (Charles DW, 
2007) frequently associated with treatment failure, relapse and high incidences of adverse drug 
reactions, which lead to prolonged illness, disability and death as a consequence. Some 
hypothesis reports suggest adverse effects of HIV, like diabetes mellitus on the treatment 
outcome of TB patients with an increased rate of failures, deaths, and defaults (www.japi.org, 
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2009).  Prompt initiation of antiretroviral therapy may be one way to decrease the alarmingly 
high death rate among HIV-infected patients with multidrug-resistant tuberculosis (www. 
publichealth.cacountry.gov, 2008). 
2.18 Experimental hypothesis  
1 There is a difference in the cure rates of MDR-TB between HIV (-) and HIV (+) patients 
at Brewelskloof hospital.  
2. The cure rate among HIV (+) patients will be affected by the use of ART drugs. 
2.19 Null hypotheses  
1. There is no difference between the cure rate of MDR-TB for HIV (+) patients and HIV (-
) patients at Brewelskloof hospital. 
2. The cure rate among HIV (+) patients will not be affected by the use of ART drugs.  
 
 2.20  Research questions  
1. What are the treatment outcomes of MDR-TB patients and patients co-infected with 
MDR-TB and HIV? 
2.  What are the reasons for the low cure rate of MDR-TB in patients who are HIV 
negative? 
3. Does HIV infection influence MDR-TB treatment outcomes?  
4. Do antiretroviral drugs have any impact on MDR-TB treatment outcomes among HIV (+) 
patients? 
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2.21 Objectives of the study 
The objectives of the study are: 
1. To find out whether HIV infection has an impact on the following treatment outcomes in 
MDR-TB patients: cure rate and treatment failure at Brewelskloof hospital.  
2. To investigate any drug interactions between ARVs and second line anti-TB drugs which  
could have an impact on the following MDR-TB treatment outcomes : cure rate and treatment 
failure at Brewelskloof hospital.  
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CHAPTER THREE 
 
METHODS 
 
3.1 Study design 
The study was designed as a retrospective case control study comparing MDR-TB treatment 
outcomes in HIV – positive patients (experimental group) and HIV-negative patients (control 
group).  
3.2 Study site 
The study was conducted at Brewelskloof hospital (BH) in Cape Winelands East and Overberg 
District of Worcester, Western Cape province; South Africa. Brewelskloof Hospital is one of the 
South African hospitals specialized in the management of MDR-TB. Patients are referred from 
state and private hospitals, general practitioners and primary health care clinics. Brewelskloof 
Hospital serves approximately 1.3 million people and receives (ukpmc.ac.uk) approximately 100 
referrals per month.  
Brewelskloof hospital covers areas like Ceres, Matjiefontein, Touws River, De Doorns, 
Robertson, Montagu, part of Stellenbosch, Swellendam, Heidberg, Riviersonderend, Caledon, 
Grabouw, Kleinmond, Hermanus, Bredasdorp, Klein Bay and Part of Paarl (see Figure 1). 
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 CAPE WINELANDS EAST DISTRICT  OVERBERG DISTRICT 
 
Figure1. Map of the Western Cape Province  
3.3 Inclusion criteria 
A patient was included in the study only if he/she complied with all the following criteria: 
1. MDR-TB sensitive to second line anti-TB drugs. 
2.  MDR-TB sensitive to second line anti-TB drugs and co-infected with HIV.  
4. Completion of treatment between 1 January 2006 and 31 December 2008. 
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3.4 Exclusion criteria 
Any case of XDR-TB was excluded in this study. 
3.5 Antituberculosis medications used at Brewelskloof hospital 
The drugs used to treat MDR-TB patients at BH involve a combination of the following first and 
second-line drugs:  ethambutol, pyrazinamide, kanamycin, ofloxacin, ethionamide and 
cycloserine. Ethambutol and pyrazinamide are still used in patients where resistance to 
ethambutol and pyrazinamide is not confirmed.  
3.6 Data collection  
 Data was collected from TB registers and clinical records of all MDR-TB and MDR-TB patients 
co-infected with HIV who finished their treatment at BH, from 1 January 2006 to 31 December 
2008. All data collected was entered into a database using Excel (Microsoft Office 2003). Data 
collection form was used to collect data from registers (see appendix III). Information about the 
patients includes patients demographisc, age distribution, patient biological profile, and number 
of patients per anti-TB drugs, drug interaction between ARVs and anti-TB drugs; and duration of 
ARVs therapy before the start of MDR-TB treatment outcomes.  
3.7 Validity and reliability of data collected 
The patients’ folder and TB register was made available by the sister-in charge for data 
collection. The patient’s information officer was around to check for completeness and accuracy 
of information on the database of the hospital. Data for this study is available on the hospital data 
base.  
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3.8. Treatment outcomes used 
Standard WHO definitions for TB disease classification, registration and treatment outcomes 
categories were applied. Treatment outcomes included cured or treatment completed failure, 
default, transfer-in and death.  
3.9 Statistical analysis 
All quantitative variables were analysed using medians as a measure of location and either range 
or interquartile range as measure of spread.  Nominal variables were descriptively analysed using 
frequency distributions indicating the absolute and relative frequencies.  Data was displayed 
graphically using histograms, bar charts or box and whisker plots where applicable.  Differences 
in quantitative variables between the HIV (+) and HIV (-) groups were analysed using a Mann-
Whitney U test.  The primary analysis was to determine whether there is a difference in cure rate 
between the HIV (+) and HIV (-) groups.  For this comparison the Pearson’s chi-square test was 
used and the Fisher’s Exact test used as small expected frequencies were evidenced.  A 
significance level of 5% was applied throughout. 
3.10 Ethical considerations  
Ethical approval was obtained from the Ethics committee of the University of the Western Cape 
for the study (Ethics registration number 09/3/18, Appendix I). 
The permission to conduct the study at Brewelskloof Hospital was granted by the Western Cape 
Department of Health (Ref: 19/18/RP87/2009, Appendix II). 
The study was done in accordance with Helsinki Declaration and confidentiality was observed.  
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3.11 Dissemination of research results 
 This study results will be disseminated through the following: 
a. Presentation at department, School of Pharmacy, University of the Western Cape 
b. Conference presentations at the national and international level 
c. Publication in scientific journal 
d. Thesis for masters degree at the University of the Western Cape 
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CHAPTER FOUR 
 
 
RESULTS 
  
4.1: Patient demographics  
As indicated in table 4.1, 336 patients started MDR-TB treatment between the 1st of January  
2004 and 31st December 2006 at Brewelskloof hospital. These patients included 242 (72%) 
MDR-TB patients and 94 (27.9%) MDR-TB patients co-infected with HIV. The 242 patients  
with MDR-TB, include 167 (71.0%) male and 75 (30.9%) female. The 94 patients with MDR- 
TB co-infected with HIV include 51 (54.2%) male and 43 (45.7%) female.  
 
Table 4.1: Patients’ demographics data per year 
 
Years 
Patients with MDR-TB   Patients with MDR-TB + HIV  
Number /year/gender (%) 
 
Number/year/gender (%) 
 
 Male 
 
Female 
 
Total (M+F) Male 
 
Female 
 
 
Total (M+F) 
2006 44 (74.5) 15(25.4) 59 14(58.3) 10(41.6)  24 
2007 56 (72.7) 21(27.2) 77 20 (54.0) 17 (45.9)  37 
2008 67 (63.2) 39(36.7) 106 17 (51.5) 16(48.4)  33 
Total  167(71.3) 75(30.7) 242 51(54.2) 43(45.7)  94 
 
Key: M= Male; F= Female; MDR-TB= Multidrug-resistant tuberculosis; MDR-TB + HIV= 
Multidrug-resistant tuberculosis co-infected with HIV. 
4.2: Age distribution 
The patients are categorized into groups of 10 years intervals. 
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Table 4.2: Age distribution 
 
Age Patients with MDR-TB Patients with MDR-TB & HIV 
 Number/ gender / (%) / n Number/ gender / (%) / n 
 Male Female Total (M+F) Male Female Total (M+F) 
0-14 10(66.6) 5(33.3) 15 3(50) 3(50) 6 
15-24 22(68.7) 10(31.2) 32 5(45.4) 6(54.4) 11 
25-35 44(65.6) 23(34.3) 67 13(59) 9(40.9) 22 
35-45 48(65.7) 25(43.2) 73 18(51.4) 17(48.5) 35 
45-55 30(78.9) 8(21) 38 6(54.5) 5(45.4) 11 
55   
and  
older 
13(76.4) 4(23.5) 17 6(66.6) 3(33.3) 9 
Total 167(71.0) 75(30.7) 242 51(54.2) 43(45.7) 94 
Total 
(M+F) 
242(72)   94(27.9)   
 
Key for table 4.2: M= Male; F= Female; MDR-TB= Multidrug-resistant tuberculosis; MDR-TB 
+ HIV= Multidrug-resistant tuberculosis co-infected with human immunodeficiency virus; %= 
percentage; N= total number of patients. 
 
As indicated in table 4.2,  MDR-TB and MDR-TB plus HIV affect more male than female 
patients and more than 50% of patients in both HIV (+) and HIV (-) groups are between 25 and 
45 years of age.  
 
4.3: Renal and liver function:  
Renal and liver function test are not included in the TB register. 
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4.4 Influence of HIV infection on MDR-TB cure rate 
Table 4.4 shows the number of patients who were not cured and those who were cure in both 
HIV (-) and HIV (+) groups. Out of 94 MDR-TB patients co-infected with HIV, 32 (34%) were 
cured and 72 (76.5%) were not cured.  In the group of MDR-TB patients without HIV infection, 
the cure rate is 30%. The difference between both cure rates is not statistically significant (p-
value = 0.45) 
 
Table 4.4: Influence of HIV infection on MDR-TB cure rate 
 HIV (-) HIV (+) Total 
Not cured 170 
70 % 
62 
65.95 % 
232 
 
Cured 72 
30 % 
32 
34.05 % 
104 
Total 242 94 336 
 
As shown in the above table, MDR-TB cure rate 34% in HIV (+) patients with and without 
antiretroviral therapy. The difference between both cure rates in not statistically significant (p- 
value =0.45). 
 
4.5: Influence of antiretroviral therapy on MDR-TB cure rate 
Out of 94 HIV (+) patients, 54 patients were on ARVs. The cure rate is 35% in the group of HIV 
(+) positive patients on ARVs and 33% in the group without ARVs. 
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Table 4.5: Influence of antiretroviral therapy on MDR-TB the cure rate  
  
ARVs No Yes Total 
Not cured 27 
67% 
35 
64% 
62 
Cured 13 
33% 
19 
35% 
32 
Total 40 54 94 
 
The difference between both cure rates is not statistically significant (p- value = 0.79) 
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4.6: Number of patients per antituberculosis drugs 
This table details the anti-TB drugs that were used by the patients during the treatment period.  
 
Table 4.6: Number of patients per antituberculosis drugs 
Drug Patients treated  for MDR-TB = 242 Patients treated for MDR-TB co-infected 
with HIV = 94 
 Number/ gender / (%) / n Number/ gender / (%) / n 
 Male Female Total (M+F) Male Female Total (M+F) 
Pyrazinamide 167(69.2) 75(30.7) 242 51(54.2) 43(45.7) 94 
Ethambutol 167(69.2) 75(30.7) 242 51(54.2) 43(45.7) 94 
Kanamycin 167(69.2) 75(30.7) 242 51(54.2) 43(45.7) 94 
Ofloxacin 167(69.2) 75(30.7) 242 51(54.2) 43(45.7) 94 
Ethionamide 167(69.2) 75(30.7) 242 51(54.2) 43(45.7) 94 
Cycloserine 167(69.2) 75(30.7) 242 51(54.2) 43(45.7) 94 
CTX 
prophylaxis 
0 0 0 58(61.7) 36(38.2) 94 
 
Key to table 4.6: CTX= Co-trimoxazole; MDR-TB= Multidrug-resistant tuberculosis; MDR-TB 
+ HIV= Multidrug-resistant tuberculosis co-infected with human immunodeficiency virus; %= 
percentage. M=male; F=female. N= total number of patients 
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All MDR-TB patients, HIV infected or not, were treated with pyrazinamide, ethambutol, 
kanamycin, ofloxacin, ethionamide and cycloserine. 
Out of 94 HIV - positive patients recorded, 58(61.7%) male and 35 (38.2%) female patients were 
given CTX prophylaxis. Furthermore, all 94 HIV positive patients were receiving ARVs as 
shown in table 4.6. 
 
4.7: MDR-TB treatment failures 
 As indicated in table 4.7, MDR-TB treatment failed in 232 (166 HIV – negative plus 66 HIV-
positive) patients out of 346 involved in the study. Furthermore, table 4.7 shows that 65 (28.0%) 
patients completed MDR-TB treatment but could not be classified as cured or failure,  29 
(12.5%) patients failed, 76 (32.7%) defaulted, 18 (7.7%) were transferred out and 44 (18.9%) 
died. As far as treatment completed and defaulted is concerned, there is no significant statistical 
difference between HIV (+) and HIV (-) The number of patients who failed the MDR-TB 
treatment and who were transferred out is significantly higher in the HIV (-) group than in the 
HIV (+) group. Finally the number of MDR-TB patients who died is significantly higher in the 
HIV (+) group). 
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Table 4.7: Treatment failures 
MDR-TB 
treatment 
outcomes 
HIV (-) MDR-TB patients HIV (+) MDR-TB patients Total  
 
 Male Female Total  Male Female Total 
 
Total  
Treatment 
completed 
26 23 49 
(29.5%) 
10 6 16 
(24.2) 
65(28.0%) 
Failure 19 5 24 
(14.4%) 
4 1 5 
(7.5%) 
29(12.5%) 
Defaulted  34 18 52 
(31.3%) 
14 10 24 
36.3%) 
76(32.7%) 
Transfer 
out 
11 2 13 
(7.83) 
3 2 5 
(7.5%) 
18(7.7%) 
Died 25 3 28 
(16.8%) 
10 6 16 
(24.2%) 
44(18.9%) 
Total 115 51 166 
(71.5%) 
41 25 66 
(28.4%) 
232 
 
Key to table 4.7: MDR-TB= Multidrug-resistant tuberculosis; MDR-TB + HIV= Multidrug-
resistant tuberculosis co-infected with human immunodeficiency virus; %= percentage.  
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4.8: Duration of antiretroviral therapy before the start of multidrug-resistant 
tuberculosis treatment  
As shown in table 4.8, the antiretroviral drugs used in HIV (+) patients include stavudine, 
lamivudine and efavirenz. The antiretroviral treatment was given to 54 (57.4%) MDR-TB 
patients co-infected with HIV. 
According to the results shown in (table 4.9), the median (range) duration of antiretroviral 
therapy before starting anti-tuberculosis drugs is 10.5 (1-60) months in patients who are taking 
ARVs before the start of MDR-TB treatment. 
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Table 4.8: Duration of antiretroviral therapy before the start of multidrug-resistant tuberculosis 
treatment  
Total number of Patients Total number of Months Drugs used 
4  1 d4T, 3TC and EFV 
6 2 d4T, 3TC and EFV 
4 3 d4T, 3TC and EFV 
2 4 d4T, 3TC and EFV 
2 5 d4T, 3TC and EFV 
1 6 d4T, 3TC and EFV 
1 7 d4T, 3TC and EFV 
2 8 d4T, 3TC and EFV 
1 10 d4T, 3TC and EFV 
1 11 d4T, 3TC and EFV  
2 12 d4T, 3TC and EFV 
1  13  d4T, 3TC and EFV 
1   14  d4T, 3TC and EFV 
 2  15   d4T, 3TC and EFV 
9  24   d4T, 3TC AND EFV 
3 30 d4T, 3TC and EFV 
1 36  d4T, 3TC and EFV 
1 60 d4T, 3TC and EFV 
Median (range) 10.5 (1-60)  
 
 
 
 
 
 
 
 
66 
 
Key for table 4.9: ART= Antiretroviral treatment; MDR-TB= Multidrug-resistant tuberculosis; 
MDR-TB + HIV= Multidrug-resistant tuberculosis co-infected with human immunodeficiency 
virus; d4T= stavudine ®; 3TC= lamivudine; EFV= efavirenz. 
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                                             CHAPTER FIVE 
 
    DISCUSSION  
 The study was designed as a retrospective case control study comparing the treatment outcomes 
of MDR-TB between two groups of patients including HIV – positive patients (experimental 
group) and HIV-negative patients (control group) both of them infected with MDR-TB.  
It was hypothesized that there is a difference in MDR-TB cure rate between HIV – positive and 
HIV- negative patients and that antiretroviral drugs could influence the MDR-TB treatment 
outcomes. 
The demographic characteristics (gender and age)  of patients involved in this study are well 
distributed into HIV (+) and HIV (-) patients. The sample size is big enough to confirm the study 
hypotheses. 
5.1 Age distribution 
Firstly, the result in table 4.2 shows that in Brewelskloof hospital, MDR-TB is common with 
working class population (25-55 years), who are sexually active; when compared with statistics 
from the United States of America, that show that TB is mainly a disease of 55 years and older or 
of the immunocompromised (Kumar et al, 2007; WHO, 2006).  
 
In the study, there were differences in study population which includes 0-14, 15-24, 25-35, 45-
55, and older. These differences are unlikely to reverse the conclusions of this study; as 
compared to similar study with bias and excluded population: the excluded group had a larger 
number of older patients (≥ 50 years) (Pillai et al, 1997).  
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5.2 Number of patients per antituberculosis drugs. 
 
In South Africa, prophylaxis co-trimoxazole preventative therapy (CPT) is for prophylaxis and 
treatment of Pneumocystis jirovecii formerly P. carinii infections. Co-trimoxazole has been made 
available in all the clinics and hospitals for use on all TB and MDR-TB patients co-infected with 
HIV. Similar to anti-retroviral treatment, the current National HIV/AIDS policy allows for the 
provision of CPT to all HIV positive TB patients with WHO stage 3 of TB or 4 HIV, WHO stage 
1  with CD4+ T-lymphocyte <200 cells/mm3, or WHO stage 2 with total lymphocyte count 
<1200 cells/mm3 Department of Health (National, 2010).          
This study is similar to other studies done in Malawi, Ivory Coast, and South Africa which 
demonstrated a 46% mortality reduction for HIV-infected TB patients taking CPT prophylaxis 
(Mwaungulu et al, 2004; Dean et al, 1999 and Hoffman et al, 2010).  
In addition, all MDR-TB patients with HIV infected or not, were treated with pyrazinamide, 
ethambutol, kanamycin, ofloxacin, ethionamide and cycloserine. The treatment of MDR-TB is 
usually continued for -24 months rather than 12-18 months for drug-sensitive drug (Katherine et 
al 2008). In this study, the MDR-TB co-infected with HIV cure rate are 32.1%; which is within 
the range when compared with multidrug resistant tuberculosis cure rate are 30 – 50% in patients 
without HIV infection Department of Health (National, 2006). 
There were 69.2% males and 30.2% females that were treated second-line anti-TB drugs and 
54.2% males and 44.7% females that were treated with ART. The result shows that there were 
more males than females in both groups. This is similar to other study conducted at Vietnam 
where there were more males than females with 79% males and 21% females (Thuy et al, 2007)  
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5.3 Drug interactions between antiretroviral and antituberculosis drugs 
There are 94 MDR-TB co-infected with HIV-positive, who received ARVs and 242 MDR-TB  
without HIV infection. The results show MDR-TB treatment outcomes as having 32.1% cured 
rate and 12.7% failures rate. This could mean that the failure was due to drug-drug interactions 
and not from HIV infections; because all MDR-TB co-infected with HIV received co-
trimoxazole prophylaxis (27.9%) and MDR-TB without co-trimoxazole (72%). It has a statistical 
significance P- value of less than 0.001. 
Immuno-compromised patients are at a high risk of drug-drug interactions during their TB 
 treatment. This study shows that was drug-drug interactions between ART and anti-TB drugs 
where we 32.1% cured rate,  treatment completed rate 26.7%, 12.7% failure rate, 33.3%  
defaulted rate, 7.9% transfer-out and 19.2% death rate.  However, there are no published studies  
of possible drug-drug interactions between second-line antituberculosis drugs and antiretroviral  
drugs (Weyer, 2005). In addition, anti-TB drugs poor absorption has been reported in HIV- 
infected patients with association to HIV-enteropathy; and poor absorption of anti-TB drugs  
resulted in drug sub-therapeutic serum concentration levels with high treatment failure, relapse,  
and acquired drug resistance (Patel et al; 1995; Peloquin et al; 1996; Weiner et al; 2005). It has  
been reported that anti-TB drugs serum (peak) concentrations were lower in TB patients co- 
infected with HIV and having CD4   cell count <200 cell/mm³ (Peloquin et al; 1996).  Also, that  
the patients that died could be as result of renal or kidney problems and not from HIV because all 
 MDR-TB co-infected with HIV is on co-trimoxazole prophylaxis. 
There was relationship between MDR-TB (HIV negative) and (HIV positive) and the differences 
between HIV negative and HIV positive are in the used of ARVs. In addition, there are drug-
 
 
 
 
 
 
 
 
70 
 
drug interactions between ART and anti-TB drugs. The only anti-TB drug that has drug 
interaction with ART is ethionamide which is thought to be metabolized by the CYP450 system, 
though it is not known which of the CYP isozymes are responsible (Burman et al, 1999).  
In this study, there was high failure and defaulted rate which is similar to what Cohn and 
Flament-Saillour et al reported in MDR tuberculosis treatment that is complicated and frequently 
associated with treatment failure, relapse and high incidences of adverse drug reactions, which 
lead to prolonged illness, disability and death as a consequence (Cohn, 1995; Flament-Saillour et 
al, 1999). In addition, this study showed mortality rate of 19.2% when compared with similar 
study with mortality rates of 72-89% (Cohn, 1995). Deaths during treatment caused by MDR-TB 
infection or by other HIV-related diseases are more frequent, particularly, in the advanced HIV-
infection stages (Cohn, 1995). 
 
 5.4 Duration of antiretroviral therapy before the start of multidrug-resistant 
tuberculosis treatment 
We have already demonstrated that human immunodeficiency virus infection does not influence 
MDR-TB treatment outcomes, since no difference in the treatment outcomes was found between 
the group of patients MDR-TB co-infected with HIV and the group of MDR-TB patients without 
HIV - infection. Furthermore, since there is no difference between the treatment outcomes within 
the group of MDR-TB patients co-infected with HIV and taking ARVs and the group of  MDR-
TB patients with HIV – infection but not receiving ARVs. We can state that antiretroviral 
therapy does not have any effect on the MDR-TB treatment outcomes. 
Finally, does the duration of antiretroviral therapy have any impact on the MDR-TB treatment 
outcomes? The answer to this question can be found in table 4.8. In that table the median (range) 
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duration of antiretroviral treatment before MDR-TB therapy is 10.5 (1-60) months. This duration 
is long enough to show any influence antiretroviral therapy might have on MDR-TB treatment 
outcomes if any. Therefore, we can conclude that, neither the fact of being on ARVs nor the 
duration of antiretroviral therapy does influence MDR-TB treatment outcomes. 
5.5 Were objectives of the study achieved? 
Yes the objectives of the study were achieved. Firstly, the study found that HIV infection does 
not have an impact on the cure rate and the treatment failure at Brewelskloof hospital. Secondly, 
no drug interactions were found between antiretroviral drugs and second-line antituberculosis 
agents. Thirdly, the fact of taking ARVs drugs does not influence the above mentioned MDR-TB 
treatment outcomes. 
5.6 Limitations of the study 
This was a retrospective study. Therefore, data collection was based on the available clinical 
records and on the data available in the tuberculosis register. The CD4 counts and viral load were 
not included in the TB register. This is an important limitation since we do not know how the 
biological profile of each patient was. 
Renal and liver function test were not included in the TB register as well. Therefore, this study 
could not investigate the influence of liver and renal diseases on the MDR-TB treatment 
outcomes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
CHAPTER SIX 
 
  
6 CONCLUSIONS and RECOMMENDATIONS  
6.1 Conclusions 
This retrospective study was conducted at Brewelskloof hospital in order to investigate the 
MDR-TB treatment outcomes in patients with MDR-TB and in patients with MDR-TB co-
infected with HIV infection who started their treatment between January 2004 and December 
2006. 
Firstly, the study demonstrated that there is no difference in the MDR-TB cure and failure rates 
in HIV (-) and HIV (+) patients. Secondly, the MDR-TB cure rate at Brewelskloof between 
January 2004 and December 2006 was similar to the MDR-TB cure rate at the national level. 
Thirdly, according to this study results, antiretroviral therapy does not affect the MDR-TB 
treatment outcomes. 
If HIV infection and antiretroviral drugs do not influence the MDR-TB cure rate, which other 
factors could keep it as low as 32% at Brewelskloof hospital? 
6.2 Recommendations 
Further studies involving a higher number of patients with similar virological profile are needed 
in order to confirm that HIV does not have any impact on MDR-TB treatment outcomes.  
Finally, studies focusing on the real causes of factors such as relapse, defaulting and failure 
leading to death need to be undertaken. These studies would also have to find out whether the 
drugs currently used for the treatment of MDR-TB are indeed effective. 
Last but not the least, the actual mechanism by which resistance to antituberculosis occurs needs 
to be clarified      
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     Appendix III  
The data collection tool 
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